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1. INTRODUCTION 
 
1.1.ORAL DRUG DELIVERY
1,2
 
Oral route is the most acceptable route of drug administration among all routes that 
have been explored for the systemic delivery of drug via various pharmaceutical products of 
different dosage form. Solid medicaments may be administered orally as powders, pills, 
cachets, capsules or tablets. These dosage forms contain a quantity of drug which is given as 
a single unit and they are known collectively as solid unit dosage forms, even in the case of 
sustained action preparations which, technically, contain the equivalent of several normal 
doses of drug. The stringent formulation requirements of modern medicaments, the many 
advantages of tablet and capsule medication, coupled with expanding health services and the 
commitment need for large scale economic manufacture, have led to a steady decline in the 
prescribing of powders and pills. Tablets and capsules, on the other hand, currently account 
for well over two third of the total number and cost of medicines produced all over the world. 
1.2.TABLETS
3
 
 Tablets are solid dosage forms usually obtained by single or multiple compression of 
powders or granules. In certain cases tablets may be obtained by moulding or extrusion 
techniques. They are uncoated or coated. Tablets are normally right circular solid cylinders, 
the end surfaces of which are flat or convex and the edges of which may be bevelled. They 
may have lines or break-marks (scoring), symbols or other markings. Tablets containing 
active ingredients having a narrow therapeutic window should generally not be presented 
with break-marks for subdivision. Non-functional break-marks should be avoided. Tablets 
contain one or more active ingredients.  
Advantages of Tablets
4,5
 
Some of the potential advantages of tablets are as follows. 
1. The unit dosage form having greatest capabilities amongst all the oral dosage form 
for the dose precision and least content variability. 
2. Cost is lowest of all oral dosage form.  
3. Lighter and compact. 
4. Easiest and cheapest to package and strip. 
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5. Easy to swallowing with least tendency for hang‐ up. 
6. Sustained release product is possible by enteric coating. 
7. Objectionable odour and bitter taste can be masked by coating technique. 
8. Suitable for large scale production.  
9. Greatest chemical and microbial stability over all oral dosage form.  
Disadvantages of tablets
 
1. When the dose of drug is large, tablets might be to big for children or even adults 
to swallow. 
2. Some drugs resist compression into dense compacts, owing to amorphous nature, 
low density character. 
3. Drugs with poor wetting, slow dissolution properties, optium absorption high in 
GIT may be difficult to formulate or manufacture as a tablet that will still provide 
adequate or full drug bioavailability. 
4. Bitter tasting drug with an objectable odour or drugs that are sensitive to oxygen 
may require encapsulation or coating. In such cases, capsule may offer the best 
and lowest cost. 
1.2.1. ADDITIVES USED IN TABLETS
6 
Excipients are pharmacologically inactive substances included in the formulation 
which is used as a carrier of active ingredient. In a conventional tablet the excipients used in 
the tablet formulation including, 
1. Diluents/fillers 
2. Binders 
3. Disintegrants 
4. Lubricants 
5. Glidants 
6. Miscellaneous 
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Diluents 
Diluents are used to increase the bulk content of the dosage form this is done in a 
situation where the active constituent to be incorporated in the formulation is of less quantity. 
For example if the active ingredient is just 5 mg, is such a case a tablet of just 5 mg is very 
difficult to manufacture and handle too, thus the bulk content is increased by addition of 
inactive excipients. Round tablets of weight 120mg to 700mg and for oval tablets 800mg are 
easy to handle. E.g. Lactose, lactose anhydrous, lactose spray dried, directly compressible 
starch, hydrolyzed starch, MCC, other cellulose derivatives, dibasic calcium phosphate 
dihydrate, mannitol, sorbitol, sucrose, calcium sulphate dehydrate, dextrose. 
 
Binders 
These are the dry powders or liquid which are added during wet granulation to promote 
granules or to promote cohesive compact during direct compression. It provides mechanical 
strength to the tablet. Binders can be in powder form and liquid form. Examples of the 
binders are  
1. Powder binders: cellulose, methyl cellulose, polyvinyl pyrolidine, PEG. 
2. Solution binders: Gelatin, PVP, HPMC, PEG, sucrose, starch. 
 
Disintegrants 
Disintegrants are added to the formulation as it breaks the dosage form into smaller 
particles when it comes in contact with the liquid, these smaller fragments have greater 
surface area which will increase the dissolution of the drug. Various mechanisms of 
disintegrations are proposed by breaking into fragments. When the tablet comes in contact 
with the liquid, the liquid penetrates into the pores of the tablets and breaks it into fragments. 
To improve the water uptake into the pores certain hydrophilic polymers are added to the 
formulation by swelling when the tablet comes in contact with the water it swells and 
ruptures the tablet into small particles. e.g. starch, starch derivatives, clay, cellulose, 
alginates, polyvinyl pyrolidone, cross linked sodium carboxy methyl cellulose. 
 
Lubricants 
Lubricants are used to reduce the friction between the tablets and die cavity when the 
tablet die cavity is getting ejected from the die. Lack of lubricant can lead to problems like 
capping, scratch on the sides of the tablet, fragmentation of the tablet, shape out etc. Thus to 
avoid this lubricants are to be used. For a lubricant the time of addition, concentration in 
CHAPTER 1                                                                                                                                                      INTRODUCTION  
 
DEPARTMENT OF PHARMACEUTICS, S.B.C.P, SIVAKASI Page 4 
 
which it is to be added and the combination are the important parameters. e.g. stearic acid, 
stearic acid salt, stearic acid derivatives, talc, PEG, surfactants, waxes, calcium stearate and 
magnesium stearate (0.25-0.50%w/w) are the most commonly used lubricants followed by 
talc. 
 
Glidants 
Glidants are used to improve the flow property of the formulation. It reduces the 
friction between the particles and between the hopper and particles and die cavity and 
particles. Actually glidant, lubricant and anti adherent have a close relation to each other. 
They have some functions in common. Most of the glidants used are hydrophobic thus they 
are to be carefully added i.e. concentration regulated. E.g. talc, colloidal silicone dioxide, 
corn starch. 
 
Miscellaneous 
Above from the above mentioned principal ingredients following excipients also 
improve the dosage form characters they are adsorbents, flavoring agents and colouring 
agents. 
 Adsorbent 
Adsorbents are used when there is an need to add a liquid or semisolid ingredient in 
the formulation, adsorbents are capable of sorbing the liquid component on to the dry 
powder. Thus oil or liquid component can be in corporate into the powder. E.g.Magnesium 
oxide, kaolin/bentonite. 
 Flavouring agents 
These are incorporated into the formulation to improve the flavor or give a pleasant 
taste to the formulation. Flavoring agents are mostly restricted to the formulations in which 
are intended to be released in the mouth or chewable tablets. They are usually added in along 
with the granules. 
 Colourants 
Colouranats are added to the formulation in order to increase the patent compliance or 
for identification of the formulation. Usually the colurants are added in the form of insoluble 
powder or in the form as liquid in the granulation liquid. e.g. FD&C and D&C dyes and 
lakes. 
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1.2.2. TYPES OF TABLETS
7 
 
1. Tablet ingested orally 
a. Compressed tablets 
b. Multiple compressed tablets 
i. Layered tablet 
ii. Compression coated tablet 
c. Repeat action tablet 
d. Delayed action and enteric coated tablet 
e. Sugar and chocolate coated tablet 
f. Film coated tablet 
g. Chewable tablet 
2. Tablet used in the oral cavity 
a. Buccal tablet 
b. Sublingual tablet 
c. Troches and lozenge 
d. Dental cones 
3. Tablet administrated by other routes 
a. Implantable tablet 
b. Vaginal tablet 
4. Tablet use to prepare solution 
a. Effervescent tablet 
b.  Dispensing tablet 
c. Hypodermic tablet 
d. Tablet triturate 
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1.2.3. MANUFACTURING PROCESS OF TABLET
8 
 
1. Dispensing (weighing and measuring) 
Dispensing is the first step in any pharmaceutical manufacturing process. Dispensing 
is one of the most critical steps in pharmaceutical manufacturing; as during this step, the 
weight of each ingredient in the mixture is determined according to dose. Dispensing may be 
done by purely manual by hand scooping from primary containers and weighing each 
ingredient by hand on a weigh scale, manual weighing with material lifting assistance like 
Vacuum transfer and Bag lifters, manual or assisted transfer with automated weighing on 
weigh table, manual or assisted filling of loss-in weight dispensing system, automated 
dispensaries with mechanical devices such as vacuum loading system and screw feed system. 
Issues like weighing accuracy, dust control laminar air flow booths, glove boxes), during 
manual handling, lot control of each ingredient, material movement into and out of 
dispensary should be considered during dispensing. 
 
2. Sizing 
The sizing (size reduction, milling, crushing, grinding, pulverization) is an impotent 
step (unit operation) involved in the tablet manufacturing. In manufacturing of compressed 
tablet, the mixing or blending of several solid ingredients of pharmaceuticals is easier and 
more uniform if the ingredients are approximately of same size. This provides a greater 
uniformity of dose. A fine particle size is essential in case of lubricant mixing with granules 
for its proper function. Advantages associated with size reduction in tablet manufacture are as 
follows: 
 It increases surface area, which may enhance an active ingredient’s dissolution rate 
and hence bioavailability. 
 Improved the tablet-to-tablet content uniformity by virtue of the increased number of 
particles per unit weight. 
 Improved flow properties of raw materials. 
 Improved colour and/or active ingredient dispersion in tablet excipients. 
 Uniformly sized wet granulation to promote uniform drying.  
 
There are also certain disadvantages associated with this unit operation if not controlled 
properly. They are as follows: 
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 A possible change in polymorphic form of the active ingredient, rendering it less or 
totally inactive, or unstable. 
 A decrease in bulk density of active compound and/or excipients, which may cause 
flow problem and segregation in the mix. 
 An increase in surface area from size reduction may promote the adsorption of air, 
which may inhibit wettability of the drug to the extent that it becomes the limiting 
factor in dissolution rate.  
 
3. Powder blending 
The successful mixing of powder is acknowledged to be more difficult unit operation 
because, unlike the situation with liquid, perfect homogeneity is practically unattainable. In 
practice, problems also arise because of the inherent cohesiveness and resistance to 
movement between the individual particles. The process is further complicated in many 
system, by the presence of substantial segregation influencing the powder mix. They arise 
because of difference in size, shape, and density of the component particles. The 
powder/granules blending are involved at stage of pre granulation and/or post granulation 
stage of tablet manufacturing. Each process of mixing has optimum mixing time and so 
prolonged mixing may result in an undesired product. So, the optimum mixing time and 
mixing speed are to be evaluated. Blending step prior to compression is normally achieved in 
a simple tumble blender. The Blender may be a fixed blender into which the powders are 
charged, blended and discharged. It is now common to use a bin blender which blends. In 
special cases of mixing a lubricant, over mixing should be particularly monitered. The 
various blenders used include “V” blender, Oblicone blender, Container blender, Tumbling 
blender, Agitated powder blender, etc. But now a day to optimize the manufacturing process 
particularly in wet granulation the various improved equipments which combines several of 
processing steps (mixing, granulation and/or drying) are used. They are “Mixer granulator” or 
“High shear mixing machine”. 
 
4. Granulation 
Following particle size reduction and blending, the formulation may be granulated, 
which provides homogeneity of drug distribution in blend. 
 
 
 
CHAPTER 1                                                                                                                                                      INTRODUCTION  
 
DEPARTMENT OF PHARMACEUTICS, S.B.C.P, SIVAKASI Page 8 
 
5. Drying 
Drying is a most important step in the formulation and development of 
pharmaceutical product. It is important to keep the residual moisture low enough to prevent 
product deterioration and ensure free flowing properties. The commonly used dryer includes 
Fluidized bed dryer, Vacuum tray dryer, Microwave dryer, Spray dryer, Freeze dryer, Turbo  
tray dryer, Pan dryer, etc. 
6. Tablet compression 
After the preparation of granules (in case of wet granulation) or sized slugs (in case of 
dry granulation) or mixing of ingredients (in case of direct compression), they are 
compressed to get final product. The compression is done either by single punch machine 
(stamping press) or by multi station machine (rotary press). The tablet press is a high-speed 
mechanical device. It 'squeezes' the ingredients into the required tablet shape with extreme 
precision. It can make the tablet in many shapes, although they are usually round or oval. 
Also, it can press the name of the manufacturer or the product into the top of the tablet. Each 
tablet is made by pressing the granules inside a die, made up of hardened steel. The die is a 
disc shape with a hole cut through its centre. The powder is compressed in the centre of the 
die by two hardened steel punches that fit into the top and bottom of the die. The punches and 
dies are fixed to a turret that spins round. 
As it spins, the punches are driven together by two fixed cams - an upper cam and 
lower cam. The top of the upper punch (the punch head) sits on the upper cam edge .The 
bottom of the lower punch sits on the lower cam edge. The shapes of the two cams determine 
the sequence of movements of the two punches. This sequence is repeated over and over 
because the turret is spinning round. The force exerted on the ingredients in the dies is very 
carefully controlled. This ensures that each tablet is perfectly formed. Because of the high 
speeds, they need very sophisticated lubrication systems. The lubricating oil is recycled and 
filtered to ensure a continuous supply.Various types of machines are used as follows: 
 1. Single punching machines. 
 2. Multi punching machines. 
 3. Rotary tablet machines. 
 4. High speed rotary tablet machines. 
                5. Multilayer rotary tablet machines. 
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Common Stages Occurring During Compression 
 
Stage1: Top punch is withdrawn from the die by the upper cam, Bottom punch is 
lowered in the die so powder falls in through the hole and fills the die. 
 
Stage2: Bottom punch moves up to adjust the powder weight-it raises and expels 
some powder 
 
Stage 3: Top punch is driven into the die by upper cam, Bottom punch is raised by 
lower cam Both punch heads pass between heavy rollers to compress the powder. 
 
Stage 4: Top punch is withdraw by the upper cam, Lower punch is pushed up and 
expels the tablet. Tablet is removed from the die surface by surface plate. 
 
Stage 5: Returned to stage 1. 
 
Figure 1: Stages Occurring During Compression 
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7. Packaging 
Pharmaceutical manufacturers have to pack their medicines before they can be sent 
out for distribution. The type of packaging will depend on the formulation of the medicine. 
'Blister packs' are a common form of packaging used for a wide variety of products. They are 
safe and easy to use and they allow the consumer to see the contents without opening the 
pack. Many pharmaceutical companies use a standard size of blister pack. This saves the cost 
of different tools and to change the production machinery between products. Sometimes the 
pack may be perforated so that individual tablets can be detached. This means that the expiry 
date and the name of the product have to be printed on each part of the package. The blister 
pack itself must remain absolutely flat as it travels through the packaging processes, 
especially when it is inserted into a carton. This poses interesting problems for the designers. 
Extra ribs are added to the blister pack to improve its stiffness. 
 
1.3.TABLET COATING
9 
Coating is a process by which an essentially dry, outer layer of coating material is 
applied to the surface of a dosage form in order to confer specific benefits that broadly ranges 
from facilitating product identification to modifying drug release from the dosage form. After 
making a good tablet, one must often coat it. Coating may be applied to a wide range of oral 
solid dosage form, including tablets, capsules, multi particulates and drug crystals. When 
coating composition is applied to a batch of tablets in a coating pan, the tablet surfaces 
become covered with a tacky polymeric film. Before the tablet surface dries, the applied 
coating changes from a sticky liquid to tacky semisolid, and eventually to a non-sticky dry 
Surface pans. The entire coating process is conducted in a series of mechanically operated 
acorn-shaped coating pans of galvanized iron stainless steel or copper. The smaller pans are 
used for experimental, developmental and pilot plant operations, the larger pans for industrial 
production. 
 
Basic Principles involved in Tablet Coating
10,11 
Tablet coating is the application of coating composition to moving bed of tablets with 
concurrent uses of heated air to facilitate evaporation of solvent.  
1. Solution in which influences the release pattern as little as possible and does 
not markedly change the appearance. 
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2. Modified release with specific requirement and release mechanism adapted to 
body function in the digestive tract. 
3. Colour coating which provides insulation. 
4. To incorporate another drug or formula adjuvant in the coating to avoid 
chemical incompatibilities or to provide sequential drug release. 
 
1.3.1. COATING PROCESS DESIGN & CONTROL  
In most coating methods, when the tablets are being agitated in a pan, fluid bed, etc. at 
that time spraying on tablets by coating solution takes place. As the solution is being sprayed, 
a thin film is formed that adheres directly to each tablet. The coating may either be formed by 
a single application or may be built up in layers through the use of multiple spraying cycles
7
. 
Firstly, uncoated tablets are placed in the pan, which is typically tilted at an angle from the 
horizontal, and then the liquid coating solution is introduced into the pan while the tablets are 
tumbling.  
By passing air over the surface of the tumbling tablets, the liquid portion of the 
coating solution is then evaporated. In comparison, a fluid bed coater operates by passing air 
through a bed of tablets at a velocity sufficient to support and separate the tablets as 
individual units. Once separation takes place, then the tablets are sprayed with the coating 
composition
12,13,14
.  
The coating process is usually a batch operating task consisting of the following 
phases:  
 Identification of batch and Recipe selection (film or sugar coating) 
 Loading/Dispensing (accurate dosing of all required raw materials) 
 Warming 
 Spraying (Both application and rolling are carried out simultaneously)  
 Drying 
 Cooling 
 Unloading 
Coating Equipment 
 A modern tablet coating system combines several components  
 A coating pan  
 A spraying system  
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 An air handling unit  
 A dust collector  
 
Advantages of Tablet Coating
15,16 
1. Tablet coatings must be stable and strong enough to survive the handling of the tablet, 
must not make tablets stick together during the coating process, and must follow the 
fine contours of embossed characters or logos on tablets.  
2. Coatings can also facilitate printing on tablets, if required. Coatings are necessary for 
tablets that have an unpleasant taste, and a smoother finish makes large tablets easier 
to swallow.  
 
Disadvantages of Tablet Coating 
1. Disadvantages of coating such as relatively high cost, long coating time and high bulk 
have led to the use of other coating materials.  
2. This process is tedious and time-consuming and it requires the expertise of highly 
skilled technician. 
 
1.4. ENTERIC COATING16-18 
A tablet that has a special outer covering designed to dissolve in the small intestine. 
Once the enteric-coating is dissolved the tablet disintegrates and the active ingredient can be 
absorbed by the patient.  An enteric coating is a barrier that controls the location of oral 
medication in the digestive system where it is absorbed. The word “enteric” indicates small 
intestine; therefore enteric coatings prevent release of medication before it reaches the small 
intestine. The enteric coated polymers remain unionize at low pH, and therefore remain 
insoluble. But as the pH increases in the GIT, the acidic functional groups are capable of 
ionization and the polymer swells or becomes soluble in the intestinal fluid. Materials used 
for enteric coatings include CAP, CAT, PVAP and HPMCP, fatty acids, waxes, shellac, 
plastics and plant fibers.  
There are four reasons for putting such a coating on a tablet or capsule ingredient: 
Protection of active pharmaceutical ingredients, from the acidic environment of the stomach 
(e.g. enzymes and certain antibiotics). 
 To prevent gastric distress or nausea from a drug due to irritation (e.g. sodium 
salicylate). 
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 For the delivery of drugs that are optimally absorbed in the small intestine to 
their primary absorption site in their most concentrated form. 
 To provide a delayed-release component for repeat action. 
 Required for minimizing first pass metabolism of drugs. 
The choice of the polymer and the thickness of the coated layer are critical to control 
the pH solubility profile of the enteric coated dosage form.  
 
1.4.1. PROPERTIES OF ENTERIC COATING MATERIAL  
1. Resistance and susceptibility  
2. Stability and compatibility  
3. Low cost and non-toxicity  
4. Ease of application without specialized equipment.  
5. Ability to be readily printed or to allow film to be applied to debossed tablet.  
6. Formation of continuous (uninterrupted) film.  
 
1.4.2. COMPOSITION OF ENTERIC COATED TABLET  
The Enteric coated formulation usually contains the following component  
a) Polymer.  
b) Plasticizer.  
c) Solvent.  
d) Colourant.  
 
a). Polymers 
Polymers are substance containing a large number of structural units joined by the 
same type of linkage. These substances often form into a chain-like structure starch, 
cellulose, and rubber all possess, polymeric properties.  
With an acid-resistant property, enteric coating polymers generally possess free 
carboxylic acid groups on the polymer backbone. They are insoluble in acidic media but 
become deprotonated and dissolved in basic media at pH nearly neutral values (pH>5). 
 
b). Plasticizer 
Success of enteric coating efficiency mostly relies on the addition of plasticizers. 
Plasticizers are a group of auxiliary components that improve elasticity of the polymeric film. 
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A wide range of plasticizers are available to the formulator such as phthalate esters, 
phosphate esters, other esters like citrates, stearates, sebacate, oleate, adipate etc. oils, 
glycerol, glycols etc.  
 
The type of plasticizer should be selected carefully as it influences the film brittleness, 
compatibility with the coating substrates and product stability. Hydrophilic plasticizer, 
triethyl citrate, is reported to improve the property of Eudragit L 30 D-55 film in the soft 
gelatin capsule formulations regardless of the type of filled liquid whereas hydrophobic 
plasticizer, tributyl citrate, gives satisfactory enteric protection only with hydrophobic filled 
liquid. The latter plasticizer could migrate to the hydrophobic filled liquid upon storage, 
resulting in the reduction of the enteric protection.  
 
c). Solvent 
Solvents are used to dissolve or disperse the polymers and other additives and convey 
them to substrate surface.  
1. Water.  
2. Alcohols.  
3. Ketones.  
4. Esters.  
5. Chlorinated Hydrocarbons.  
 
d). Additives 
The properties and composition of other components of the film coating formulation 
also need to be considered and optimized to get the most desired effects without affecting the 
quality of the film. Various other components which could be used in coating formulation 
are: 
 
 Pigments/Colorant  
The commonly used colorants in coating are water soluble dyes. However, the overall 
colour effect of these dyes depend on the dye concentration at a particular point, thickness of 
film at that point and the residual moisture content in the film at that point. As these 
parameters can differ from tablet to tablet, the colour difference among various tablets within 
the same batch may become very visible.  
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 Opacifier  
The opacity of the film depends on the difference between the refractive index of the 
polymer and other components of the coating formulation. The lake colours used in enteric 
coating has refractive index similar to that of various polymers, thus the opacity of lake 
colours is very poor.eg Titanium Oxide.  
 Anti-tacking agent  
The most commonly used anti- tacking agent is Talc, which if used in higher 
concentration tends to settle down from the coating suspension, thus affecting the 
composition of suspension during the coating process.  
 
1.4.3. DEFECTS OCCOUR IN COATED TABLETS 19-22 
Here is a list of common defects associated with coated tablets and some likely causes 
and the remedies.  
 
1) Picking and sticking 
This is when the coating removes a piece of the tablet from the core. Over wetting or 
excessive film tackiness causes tablets to stick to each other or to the coating pan. On drying, 
at the point of contact, a piece of the film may remain adhered to the pan or to another tablet, 
giving a “picked” appearance to the tablet surface and resulting in a small exposed area of the 
core. It is caused by over-wetting the tablets, by under-drying or by poor tablet quality.  
Remedy 
A reduction in the liquid application rate or increase in the drying air temperature and 
air volume usually solves this problem. Excessive tackiness may be an indication of a poor 
formulation.  
 
2) Twinning 
This is the term for two tablets that stick together and it is a common problem with 
capsule shaped tablets.  
Remedy 
 Assuming you don’t wish to change the tablet shape, you can solve this problem by 
balancing the pan speed and spray rate. Try reducing the spray rate or increasing the pan 
speed. In some cases, it is necessary to modify the design of the tooling by very slightly 
changing the radius. The change is almost impossible to see, but it prevents the twinning 
problem.  
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3) Colour Variation 
This problem can be caused by processing conditions or the formulation. Improper 
mixing, uneven spray pattern and insufficient coating may result in colour variation. The 
migration of soluble dyes, plasticizers and other additives during drying may give the coating 
a mottled or spotted appearance.  
Remedy 
The use of lake dyes eliminates dye migration. A preformulation with different 
plasticizers and additives is the best way to solve film instabilities caused by the ingredients. 
  
4) Orange Peel 
This refers to a coating texture that resembles the surface of an orange. Inadequate 
spreading of the coating solution before drying causes a bumpy or “orange-peel” effect on the 
coating. It is usually the result of high atomization pressure in combination with spray rates 
that are too high. This also indicates that spreading is impeded by too rapid drying or by high 
solution viscosity.  
Remedy 
Thinning the solution with additional solvent may correct this problem.  
 
5) Mottling 
This can happen when the coating solution is improperly prepared, the actual spray 
rate differs from the target rate, the tablet cores are cold or the drying rate is out of 
specification.  
 
Remedy 
 Use smaller sized granules and appropriate binding agent and change the solvent 
system and decrease the drying temperature. 
 
6) Capping and Lamination 
This is when the tablet separates in laminar fashion. Capping is partial or complete 
separation of top or bottom crowns of tablet main body. Lamination is separation of a tablet 
into two or more distinct layers. Friability test can be used to reveal these problems.  
The problem stems from improper tablet compression, but it may not reveal itself until you 
start coating.  
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Remedy 
Be careful not to over-dry the tablets in the preheating stage. That can make the 
tablets brittle and promote capping. 
 
7) Roughness 
A rough or gritty surface is a defect often observed when coating is applied by a 
spray. Some of the droplets may dry too rapidly before reaching the tablet bed, resulting in 
the deposits on the tablet surface of “spray dried” particles instead of finely divided droplets 
of coating solution. Surface roughness also increases with pigment concentration and 
polymer concentration in the coating solution.  
Remedy 
Moving the nozzle closer to the tablet bed and reducing the degree of atomization can 
decrease the roughness due to spray drying.  
 
1.4.4. EVALUATION PARAMETERS23,24 
Tablets when formulated may undergo physical and chemical changes, which may 
alter their bioavailability. Therefore, the tablets are to be evaluated before dispensing to 
ensure their stability and bioavailability throughout their shelf life. Evaluation of tablets can 
be carried out by the following test. 
 
Pre-compression Parameters 
 
 Loss on drying 
 Bulk density 
 Tapped density 
 Carr’s index 
 Hausner’s ratio 
 
Evaluation of Tablets 
 
 Tablet appearance 
 Hardness  
 Thickness  
 Friability  
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 Weight variation test 
 Disintegration test 
 Drug content 
 In-vitro Dissolution test 
 
1.5. MODIFIED DRUG DELIVERY SYSTEM
26,27,28 
 Modified release DDS include systems with pH–dependent, extended, delayed or 
pulsed drug release. Sustained, extended or prolonged release drug delivery systems are terms 
used synonymously to describe this group of controlled drug delivery. 
1.5.1. CLASSIFICATION 
 The USP and NF have defined a modified release dosage forms as one in which the 
drug release characteristics of time course and location are chosen to accomplish therapeutic      
objectives not offered by conventional dosage forms. 
a. Sustained Release 
A sustained-release dosage form is designed to achieve a prolonged     therapeutic 
effect by continuously releasing medication over an extended period of time after 
administration of a single dose. These systems try to mimic zero-order release by providing 
drug in a slow first-order fashion. 
b. Controlled Release 
The term “Controlled release” has become associated with those systems from which 
therapeutic agents may be automatically delivered at predefined rates over a long period of 
time. These systems deliver drugs in a zero-order fashion. 
c. Repeat Action 
Alternative method of sustained release in which multiple doses of a drug are 
contained within a dosage form and each dose is released at a periodic interval. 
d. Site-specific and receptor targeting 
For receptor release, target is particular receptor for a drug within an organ or tissue.        
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1.5.2. DELAYED RELEASE SYSTEM
 
     The design of such system involves release of drugs only at a site in the gastrointestinal 
tract. The drugs contained in such a system are those that are: 
a) Destroyed in the stomach or by intestinal enzymes 
b) Known to cause gastric distress 
c) Absorbed from a specific intestinal site or 
d) Meant to exert local effect at a specific gastrointestinal site. 
The two types of delayed release systems are: 
 Intestinal release systems 
A drug may be enteric coated for intestinal release for several known reasons 
such as to prevent gastric irritation, prevent destabilization in gastric pH etc. 
   Colonic release systems 
Drugs are poorly absorbed through colon but may be delivered to such a site 
for two reasons.   
                        a) Local action in the treatment of ulcerative colitis 
                        b) Systemic absorption of protein and peptide drugs 
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1.5.3. DELAYED RELEASE SOLID ORAL DOSAGE FORMS 
The correct selection and balance of excipients and processes in solid dosage 
formulations are designed either for improving the micrometric or macrometric proprerties of 
materials during manufacture and for providing a desired drug delivery system
29
. The most 
commonly used pharmaceutical delayed release solid dosage forms today include tablets, 
capsules, granules, pellets. 
 
 
 
 
 
 
 
Figure 2: Relationship of Pharmaceutical Delayed Release Solid Dosage Forms 
1.5.3.1. CLASSIFICATION OF DELAYED RELEASE SOLID ORAL DOSAGE 
FORMS 
Delayed release solid oral dosage forms are available either as single unit (non divided   
formulations–tablets,capsules) or as multiple unit (divide formulations-pellets,                  
mini -tablets) forms. 
 Single unit dosage forms 
The single-unit dosage forms usually refer to diffusion controlled systems which 
include monolithic systems. Where the diffusion of a drug through a matrix is the rate 
limiting step reservoir or multilayered matrix systems
30
. Where the diffusion of the drug 
through polymer coating or layer of the system is the rate limiting step. However , generally, 
release of drugs will occur by a mixture of these two mechanisms. 
     Granule       Powder       Pellet  
     Tablet     Enteric coating      Capsule  
 Immediate release             
Controlled release                         
-Site-specific (enteric)                       
-Sustained 
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 Multi unit dosage forms31,32 
  Types of multi unit dosage forms comprise, 
a. Granules 
b. Pellets 
c. Microparticles (microspheres or microcapsules) and Nanoparticles.   
d. Mini tablets and mini depots (dispersed and distributed throughout the                          
gastro intestinal tract when the capsule or tablet disintegrates).   
e. Multi unit tablets (divided at ingestion without loss of the depot effect, as the 
sub unit act as a self contained depots). 
Therapeutic Advantage of Multi units over single units 
 When taken orally, multi unit dosage forms 
 Disperse freely in the gastro intestinal tract. 
 Provides less risk of dose dumping. 
 Reduces localized concentration of irritative drugs. 
 Reduce risk of inter and intra patient variability. 
 Improves safety and efficacy of a drug. 
 Maximize drug absorption, reduce peak plasma fluctuations, minimize local 
irritation of the mucosa by certain irritant drugs and minimize potential side 
effects without appreciably lowering drug bioavailability. 
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2. AIM AND PLAN OF WORK 
2.1. AIM AND OBJECTIVE 
 
The aim of the present investigation was to prepare delayed release i.e., enteric coated 
tablets of Rabeprazole sodium by using Methacrylic acid copolymer and to optimize coating 
process parameters by Direct compression method.  
Rabepeazole sodium is used in the treatment of acid related gastro duodenal disorders by 
reducing gastric acid secretion. Proton pump inhibitors are substituted benzimidazoles and all 
share a similar core structure and mode of action, but differ in substituent groups.  
Delayed release dosage form is best formulations which are used for drugs that are 
destroyed in the gastric fluids, or cause gastric irritation, or are absorbed preferentially in the 
intestine. Such preparations contain an alkaline core material comprising the active substance, a 
separating layer and enteric coating layer. 
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2.2. PLAN OF THE WORK 
 
The present work was carried out to formulate delayed release tablets of Rabeprazole 
sodium and to evaluate the tablets for various parameters. It was planned to carry out this work 
as outlined below. 
 
1. To Study the drug and excipient compatibility by FT-IR. 
 
2. To carry out the Pre-compression parameters of the powder blend such as  
 Angle of repose   
 Bulk Density 
 Tapped density 
 Compressibility Index 
 Hausner’s ratio 
 
3. To formulate delayed release tablets of Rabeprazole sodium by “Direct Compression 
Method” using methacrylic acid as as a copolymer. 
 
4. Evaluation of Compressed tablets 
 Hardness 
 Thickness 
 Friability 
 Weight variation 
 Estimation of drug content 
 Disintegration time 
  In-vitro release studies 
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5. Evaluation of Enteric Coated tablets 
 Thickness 
 Weight variation 
 Estimation of drug content 
 Disintegration time (Acid & Alkali Buffer) 
  In-vitro release studies using buffers 
 Optimized  formulation Vs Marketed  sample Comparison 
5. To perform stability study for the best formulation at 250C ± 2/60% ± 5%RH and      
40
0
C ± 2/75% ± 5%RH for 3 months. 
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2. LITERATURE REVIEW 
 
 
 G Sridhar Babu et al.,
33
 formulated and evaluated the delayed release tablets of Rabeprazole 
sodium, an anti ulcer drug like peptic ulcer and duodenal ulcer. Rabeprazole was class-I Proton 
pump inhibitor to gain FDA approval. Rabeprazole sodium Delayed release tablets were 
prepared by Direct Compression method using different excipients as well as with varying 
concentration of polymer proportions using HPMC Phthalate 55 (HPMCP 55) as enteric coating 
material. All the excipients are tested for compatibility with drug, which revealed that there was 
no physical and chemical interaction occurred. During compression tablet appearance, average 
weight, hardness, thickness, friability, disintegration time was evaluated and enteric coated 
tablets were evaluated for Hardness, thickness and In-vitro drug release studies. From the results 
F8 fulfilled all the specifications of the physical properties and in-vitro release and is comparable 
to the innovator product. 
 
Anroop B Nair et al.,34 formulated and evaluated the enteric coated tablets for Esomeprazole 
magnesium trihydrate. Different core tablets were prepared and formulation (F-1) was selected 
for further enteric coating, based on the disintegration time. Seal coating was applied to achieve 
3% weight gain using opadry. Enteric coating was carried out using different polymers like 
Eudragit L-30 D-55, hydroxy propyl methylcellulose phthalate, cellulose acetate phthalate and 
Acryl-EZE to achieve 5% weight gain. Disintegration studies showed that the formulations failed 
in 0.1 N HCl media. Hence the quantity of enteric coating was increased to 8% w/w. In vitro 
analysis of the developed tablets was carried out. Results from disintegration time and 
dissolution rate studies indicate that all the Esomeprazole enteric tablets prepared possess good 
integrity, desirable for enteric coated tablets. Among the polymers studied, the methacrylic 
polymers exhibited better dissolution rate than the cellulose polymers. Stability studies indicate 
that the prepared formulations were stable for a period of three months. This study concluded 
that enteric coated tablets of esomeprazole can be prepared using any of the enteric coating 
polymer studied using a minimal weight gain of 8%. 
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Sourav Tribedi et al.,
35
 formulated and evaluated of enteric coated tablets of Pantoprazole 
Pantoprazole is a proton pump inhibitor, belongs to group of benzimidazole, Pantoprazole 
sodium were prepared by direct compression method using different concentration of, 
microcrystalline cellulose as filler, mannitol and dicalcium phosphate as diluents, 
crosscarmellose sodium as disintegrating agents, magnesium stearate and talc was used as a 
glidant and lubricant respectively. Direct compression is economic compare to wet granulation 
since it requires fewer unit operations. This means less equipment, lower power consumption, 
less space, less time and less labour leading to reduced production cost of tablets. The prepared 
tablets were evaluated for hardness, weight variation, friability and drug content uniformity and 
it was found that the results comply with official standards. The prepared tablets were coated 
using enteric coating polymer such as cellulose acetate phthalate, Eudragit L100 and by dip 
coating method. The in vitro release was studied using acidic buffer pH 1.2 and phosphate buffer 
pH 6.8. Prepared all batch’s C2F9 was found best, with hardness 6.3 ± 0.14 (Kg/cm2), drug 
content 98.54 ± 0.12(%), disintegration time 6.02± 0.21(min), and percentage cumulative drug 
released which started after 120 min and reached 99.72 after 180 min. Stability studies indicated 
that the developed tablets were stable and retained their pharmaceutical properties at room 
temperature and 40 °C / 75% RH for a period of 3 month. 
 
Farha Amna Shaik et al.,
36
 formulated and evaluated Rabeprazole delayed release enteric 
tablets comparable to the innovator product. Five formulations of enteric coated tablets of 
Rabeprazole were developed by preparing core tablets using mannitol as diluents and 
Crospovidone as super disintegrant in different proportions and varying the compositions of sub 
coating and enteric coating using opadry white and enteric yellow .The core tablets were 
prepared by direct compression method. In the preformulation studies the micromeritic flow 
properties of the API were assessed by determining angle of repose, compressibility index, 
Hausner ratio. The results indicated good free flow of Rabeprazole. As such formulation F5 
developed is considered as an efficient delayed release formulations of Rabeprazole comparable 
to the innovator product. Thus the study fulfilled the objective of developing efficient 
Rabeprazole delayed release tablets. 
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Rabia Bushra et al.,
37
 formulated the enteric coated tablet of Ibuprofen (200 mg) using an 
aqueous dispersion system Ibuprofen is a propionic acid derivative that belongs to the class 
NSAIDs. Major adverse reactions associated with Ibuprofen are related to GIT and include 
peptic and mucosal ulcers, dyspepsia, severe gastric pain and bleeding, that results in excessive 
treatment failure. The goal of this study was to develop enteric coated ibuprofen tablets in order 
to avoid gastric mucosal irritation, diffusion of drug across mucosal lining and to let active 
ingredient be absorbed easily in small intestine. The formulation was developed and 
manufactured through the direct compression process, the simplest, easiest and most economical 
method of manufacturing. Enteric coating was done using an Opadry white subcoating and an 
aqueous coating dispersion of Acryl-Eze. Enteric coated formulation was subjected to 
disintegration and dissolution tests by placing in 0.1 M hydrochloric acid for 2 h and then 1 h in 
phosphate buffer with a pH of 6.8. About 0.04% of drug was released in the acidic phase and 
99.05% in the basic medium. These results reflect that Ibuprofen can be successfully enteric 
coated in order to prevent its release in the stomach and facilitate rapid release of the drug in the 
duodenum, due to the presence of superdisintegrant. Formulated this enteric coated tablets could 
increase patient compliance by decreasing adverse drug reactions (ADR
S
) associated with 
Ibuprofen therapy. 
 
Mohammed Sarfaraz et al.,
38
 developed immediate-release enteric-coated time release tablets 
of Salbutamol sulphate for the treatment of nocturnal asthma. Nocturnal asthma is an asthma 
phenotype marked by nighttime increases in airway inflammation, airway hyper responsiveness, 
and expiratory airflow limitation. The occurrence of nocturnal asthma is associated with 
increased morbidity and inadequate asthma control, and has an important negative impact on 
quality of life. Formulation of enteric-coated time release tablets with suitable lag time could 
address the problems associated with asthma. To achieve this goal, immediate release tablets 
were prepared by direct compression method using superdisintegrants that contribute to the faster 
disintegration of tablet and thereby improved solubility of the drug. Different disintegrants like 
cross caramellose sodium, crospovidone and sodium starch glycolate in different concentrations 
(2.5% to 7.5%w/w) were tried in order to further improve disintegration time. The formulation, 
which showed best disintegration and dissolution profile, was coated with ethyl cellulose as inner 
layer and Eudragit S100 as outer enteric-coating polymer which does not dissolve at gastric pH 
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but dissolve at intestinal pH, releasing the drug immediately in the alkaline medium. The 
optimized enteric-coated formulation E6 containing 2.5%w/w of Eudragit S 100 and 30%w/w of 
ethyl cellulose as coating system inhibited the release of the drug in 0.1 N HCl, and whereas 
99.04% of drug was released in the intestinal medium. Thus, dissolution profiles indicated that 
E6 tablet may be better alternative in the treatment of nocturnal asthma which overcomes the 
problems of conventional forms. 
 
N. Damodharan et al.,
39
 developed the small intestine targeting tablets of Doxycycline 
hydrochloride by wet granulation method and enteric coating of tablets (conventional standard 
coating technique).This drug is universal antibiotic and can be targeted to the specific site of 
absorption by enteric coating using pH dependant polymers .Polymers like Eudragit and HPMC 
Phthalate are selected where dissolution is above pH 6 and pH 6.4 respectively. Preformulation 
studies like angle of repose, bulk density, tapped density, porosity, Carr's index, Hausner's ratio 
were performed. Six batches (F1 to F6) were formulated and evaluated for hardness, friability, 
weight variation, drug content, disintegration and in‐vitro dissolution. Among the six batches, 
batch F4 was showing 94% drug release and was considered to be best formulation. 
 
M. Kishore et al.,40 formulated and evaluated the fabricated olsalazine sodium enteric coated 
tablets in ulcerative colitis and also compare the In-vitro dissolution profile of optimized 
Olsalazine sodium enteric coated tablets in the presence of β- glycosidase at targeted colonic 
region.The present study was fabricated to observe the drug release of Olsalazine sodium enteric 
coated tablets at targeted site specific colon region. These tablets were formulated from F1-F8 by 
selecting time dependent and release retard biodegrable polymers such as ethyl cellulose-
chitosan composite by combining with different concentrations by wet granulation. This 
composite was included in this study to control the solubility of premature drug release in 
gastrointestinal fluid and in this regard, the above formulation F6 was optimized and coated with 
Eudragit-S 100 as enteric polymer as to retard the drug release at specified site colon by 
changing suitable concentration as like 1, 3, 5, and7 %. From which F6 containing 5% Eudragit-
S 100 was shown only 75.6 % drug release in 24 hrs and also it was compared with dissolution 
medium containing β-glycosidase. In which enzymatic condition the above formulation 
enhanced the drug release i.e, 98.3% was founded in 24 hrs.  
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Muthuirulappan Thirumaran et al.,41 formulated the Paroxetine controlled release enteric 
coated tablet and its in-vitro release kinetics and stability studies. Paroxetine core tablets were 
prepared by wet granulation process using HPMC K4M and K100M as matrix forming 
hydrophilic polymers. Instacoat En II (10%) in Isopropyl alcohol (90%) was used as an enteric 
coating solution. In vitro dissolution study was performed for all the formulations by using Tris 
buffer as dissolution medium. Different dissolution models were applied to evaluate release 
mechanisms and its kinetics. The result suggests that F11 formulation showed uniform (zero 
order) release of drug from the matrix tablet with good correlation value for 12 hours. The effect 
of paddle RPM in kinetic study was also done for F11 formulation. The stability studies were 
conducted for F11 at 40
o
C ± 2
o
C / 75% RH ± 5% for a period of 3 months. No significant 
differences were observed in the release profile of different batches of each enteric coated 
paroxetine CR tablet. The similarity and dissimilarity factors for F11 were 0.68 and 95.62 
respectively. The best fit with higher correlation was found in the linear regression graph with 
the Hixon-crowel cube root law for selected formulation F11 and innovator brand. The present 
study concluded that the formulation F11 was stable and exhibited appreciable controlled release 
of an enteric coated paroxetine matrix tablet for reproducible and commercial manufacturing. 
 
B.Rama et al.,
42
 developed pharmaceutically equivalent and stable enteric-coated tablets of 
Rabeprazole sodium comparable to innovator product. Different Formulations of Rabeprazole 
core tablets were developed using mannitol as diluent and croscarmellose as super disintegrant in 
different proportions. Further optimized formulation was coated with varying the compositions 
of sub coating and enteric coating using opadry white and enteric yellow. Compatibility studies 
were performed for drug, physical mixture tablet which shows no interaction. From the 
dissolution the formulation F6 shows highest percentage of drug release. The kinetics of drug 
release for F6 & Innovator followed first order and ‘n’ value (0.5>n<1) shows that the 
mechanism may be erosion control rate release. The f1 and f2 were found to be 3.03 and 72.01 
respectively for formulation F6 and innovator product. Hence these two products were 
considered similar and comparable. In the accelerated stability testing carried out at 40°c and 
75% RH for three months, no significant change in the physical properties, drug content, and 
dissolution rate of formulation F6 was observed. From this it can be concluded that formulation 
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F6 developed is found to be an efficient delayed release formulations of Rabeprazole comparable 
to the innovator product. 
 
B.Shibu et al.,43 formulated and evaluated the enteric coated Serratiopeptidase tablets by wet 
granulation method. Serratiopeptidase is derived from bacteria belonging to genus Serratia. 
Serratiopeptidase tablets used in the treatment of viral diseases and hepatitis. Serratiopeptidase 
were formulated using HPMC phthalate as enteric coating polymer in different concentrations to 
optimize delayed drug release profile and to target the drug release in the small intestine regions. 
The present work was made to develop enteric coated tablets containing Serratiopeptidase tablets 
were made by direct compression method. The tablets were evaluated for physical 
characterization, in vitro release study and stability studies. Results of in vitro release profile 
indicated that formulation F1 was the most promising formulation as the extent of drug release 
from this formulation was optimum and match with the In-house Specification when compared 
to other formulations. 
 
Sanjay R. et al.,
44 
developed and evaluated the enteric coated tablets of Rabeprazole sodium by 
using Methacrylic acidcopolymer (Colorcoat EC4S) and to optimize coating process parameters 
which implicate more significant effects on tablet coating process. The different batches of 
uncoated tablets were prepared by both wet granulation and direct compression method. Batch 
B6 of uncoated tablets prepared by direct compression method shown good results of evaluation 
parameters compared to other batches. Results of the preliminary trials indicated that process       
parameters individually affected the quality of coated tablets. At this point of time it was seen 
that spray rate, inlet air temperature and hence to study the combined effect of this factors on the 
coating process,  full factorial design was applied. Comparative study of   dissolution profile of 
final batch with market preparations was conducted and it was concluded that final formulation F 
shown good similarity with market products. The results of the accelerated stability of final 
formulation F for 3months revealed that storage conditions were not found any significant 
changes in final formulation F. The photo instability of the Rabeprazole sodium showed by the 
photo stabilty studies indicated that special care to avoid exposure of the drug to the light effects 
must be taken during the manufacture and storage of the pharmaceutical preparations. 
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Rupesh S. Kamble. et al.,
45
 formulated and evaluated Enteric Coated Dosage Form using 
Ketorolac Tromethamine. Reduction of side effects while prolonging its action by using 
controlledrelease of oral dosage forms is highly desirable. In the present study direct 
compression method is used for the preparation of fabricated batches and EudragitL100 is used 
as coating polymer for enteric coating. In vitro release profiles of batches F1-F4 shows that 
Ketorolac Tromethamine drug:polymer ratio with Guar gum, Xanthan Gum, Ethyl cellulose and 
Sodium alginate give 79.32%, 91.52%, 88.35%and 92.19% drug release respectively in 12 hours. 
In vitro release profile of batches F5-F8 shows f 85.21%, 95.52%, 93.50%, 97.24% respectively 
in 12 hours. In vitro release profile ofbatches F9-F12 shows that Ketorolac Tromethamine in 
ratio 1:3 with Guar gum, Xanthan Gum, Ethylcellulose and Sodium alginate gives release of 
89.50%, 98.25%, 95.22%, 100.27% respectively in 12hours. 2 and then showed higher increase 
in phosphate buffer of pH 6.0 up to 12 hours. All these batches follow near zero order kinetic. 
This indicates that the Guar Gum, Xanthan Gum and Ethyl cellulose and Sodium alginate at 
minimum concentration is not only able to sustain but also control the drug release. 
 
Subramaniam Kannan et al.,
46
 formulated and evaluated the enteric coated aspirin tablets.The 
delayed release tablet is intended to  release the drug after some delay or after tablet pass GI 
tract. The enteric coating is common example of this tablet. All enteric coated tablets are delayed 
release tablet but all delayed release tablet are not enteric coated tablets.1 Aspirin delayed release 
tablet is used to increase bioavailability and to reduce risk of hospitalization for heart failure, 
coronary thrombosis deliver drug at a near constant rate for 24hr. The 2 and 10 keeping these 
factors in view it is aimed to formulate, evaluate and stabilize Aspirin (75mg) DR tablet to 
provide a controlled and predictable release of Aspirin and which is used in the treatment of 
Coronary Thrombosis (heart disease) for once in day administration. The half life of Antiplatelet 
agent is 6 Hours which makes it     suitable candidate for delayed release formulation. The 
present work aims to avoid degradation of drug in acidic environment of stomach. So due to 
enteric coating drug releases in to the small intestine so that drug gets larger surface area for 
absorption. Micro crystalline cellulose, maize starch, cross carmilose sodium is a disintegrent 
used to prepare a blend for direct compaction method. Aspirin anti-platelet compounds which 
suppress or inhibit the cyclooxygenase enzyme which is responsible for the formation of 
thromboxane A2 thus block the formation of   thromboxane A2. Thromboxane A2 is a activator 
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of platelet aggregation. Hence our present study was performed on these formulations as aspirin 
delayed release   tablet. 
 
Sumit Chakraborty, et al.,
47 
formulated and evaluated the  pantoprazole sodium enteric coated 
tablets .This compound inhibits gastric acid formation and thereby it is very efficient for the 
treatment of gastric and duodenum ulcers. In aqueous media more acidic than pH 4 it suffers a 
practically complete decomposition within a period shorter than 10 minutes. Even in solid state it 
is sensitive to heat,light and especially to substances containing an acidic group.   Pantoprazole 
which is an acid labile drug it degrade on the stomach pH can be coated with a substance that 
will only dissolve in the small intestine. For such types of drugs, enteric coating added to the 
formulation tends to avoid the stomach's acidic   exposure, delivering them instead to a basic pH 
environment (intestines pH 5.5 and above) where they do not degrade, and give their desired 
action.  
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4.1 LIST OF CHEMICALS 
 
Table 1:   LIST OF CHEMICALS AND THEIR MANUFACTURERS. 
 
S.No Materials Manufacturers 
1 Rabeprazole sodium   Metrochem API Pvt. Ltd., Hyderabad ,India 
2 Mannitol anhydrous Qingdao Bright Moon Seawood Group Co.Ltd., China 
3 Copovidone Boai NKY Pharmaceutials Ltd., China 
4 Crospovidone Boai NKY Pharmaceutials Ltd., China 
5 Light magnesium oxide Par drugs & chemicals pvt. ltd,vadodara,india 
6 Methyl paraben Rasula pharmaceuticals and fine chemicals, Hydrabad,India 
7 Propyl paraben Rasula pharmaceuticals and fine chemicals, Hydrabad,India 
8 Magnesium stearate Par drugs & chemicals pvt. ltd,vadodara,india 
9 Instacoat moist shield 
white 
Ideal Cures Pvt. Ltd., Mumbai, India 
10 Protectab Enteric M1  Bharat Coats, Chinna Salam, Kanchipuram , India 
11 Insta coat glow Ideal Cures Pvt. Ltd., Mumbai, India 
12 Lake of  ironoxide 
yellow 
koel colours pvt ltd.  mumbai , india 
13 Lake of Ironoxide red Koel colours pvt ltd.  mumbai , india 
14 Isopropyl alcohol 
Deepak Fertilisers And Petrochemicals Corporation Limited 
Pune,India 
15 Methylene dichloride Chemplast Sanmar Plant II, Mettur Dam, Salem,Tamil Nadu,India. 
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4.2. DRUG PROFILE 
 
4.1.1. RABEPRAZOLE SODIUM
47-49 
 
Rabeprazole sodium : Rabeprazole sodium is an antiulcer drug in the class 
of proton pump inhibitors. It is a prodrug - in the acid 
environment of the parietal cells it turns into active 
sulphenamide form. Rabeprazole inhibits the H+, 
K+ATPase of the coating gastric cells and dose-
dependent oppresses basal and stimulated gastric acid 
secretion. 
 
Chemical structure : 
 
 
IUPAC Name : 2-({[4-(3-Methoxypropoxy)-3-methyl-2 pyridyl] 
methyl} sulfinyl) -1H-benzimidazole sodium. 
 
Molecular formula : C18H20N3NaO3S. 
 
Molecular weight : 381.42. 
 
Description : A White or almost white powder. 
 
Melting point : 170-173 °C. 
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Solubility : Soluble in water. 
 
 
Half life :  1-2 hours (in plasma). 
 
Absorption : Absolute bioavailability is approximately 52%. 
 
Volume of distribution : 160 litre. 
 
Protein binding 
 
 
: 96.3% (bound to human plasma proteins). 
 
Pharmacodynamics 
 
: Rabeprazole prevents the production of acid in the 
stomach. It reduces symptoms and prevents injury to 
the esophagus or stomach in patients with 
gastroesophageal reflux disease (GERD) or ulcers. 
Rabeprazole is also useful in conditions that produce 
too much stomach acid such as Zollinger-Ellison 
syndrome. Rabeprazole may also be used with 
antibiotics to get rid of bacteria that are associated 
with some ulcers. Rabeprazole is a selective and 
irreversible proton pump inhibitor, suppresses gastric 
acid secretion by specific inhibition of the H
+
, K
+
 -
ATPase, which is found at the secretory surface of 
parietal cells. In doing so, it inhibits the final 
transport of hydrogen ions (via exchange with 
potassium ions) into the gastric lumen. 
 
Mechanism of action : Rabeprazole belongs to a class of antisecretory 
compounds (substituted benzimidazole proton-pump 
inhibitors) that do not exhibit anticholinergic or 
histamine H2-receptor antagonist properties, but 
suppress gastric acid secretion by inhibiting the 
gastric H
+
/K
+
ATPase (hydrogen-potassium adenosine 
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triphosphatase) at the secretory surface of the gastric  
 
parietal cell. Because this enzyme is regarded as the 
acid (proton) pump within the parietal cell, 
rabeprazole has been characterized as a gastric 
proton-pump inhibitor. Rabeprazole blocks the final 
step of gastric acid secretion. In gastric parietal cells, 
rabeprazole is protonated, accumulates, and is 
transformed to an active sulfenamide. When studied 
in vitro, rabeprazole is chemically activated at pH 1.2 
with a half-life of 78 seconds. 
 
Metabolism : Rabeprazole is extensively metabolized. The 
thioether and sulphone are the primary metabolites 
measured in human plasma. These metabolites were 
not observed to have significant antisecretory 
activity. In vitro studies have demonstrated that 
rabeprazole is primarily metabolized in the liver by 
cytochromes P450 3A (sulphone metabolite) and 
2C19 (desmethyl rabeprazole). The thioether 
metabolite is formed by reduction of rabeprazole.  
 
Route of elimination : Approximately 90% of the drug was eliminated in the 
urine, primarily as thioether carboxylic acid; its 
glucuronide, and mercapturic acid metabolites. 
 
Adverse reactions 
 
: In general, rabeprazole treatment has been well-
tolerated in both short-term and long-term trials. The 
adverse events rates were generally similar between 
the 10 and 20 mg doses. 
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Dosage and administration  
 
: Healing of Erosive or Ulcerative Gastroesophageal 
Reflux Disease (GERD): 
  The recommended adult oral dose is one 20 
mg delayed-release tablet to be taken once daily for 
four to eight weeks. For those patients who have not 
healed after 8 weeks of treatment. 
Healing of Duodenal Ulcers:  
The recommended adult oral dose is one 20 
mg delayed-release tablet to be taken once daily after 
the morning meal for a period up to four weeks. Most 
patients with duodenal ulcer heal within four weeks. 
A few patients may require additional therapy to 
achieve healing. 
 
Stability and storage : Prevent from oxidising agents. Store in a cool, dry 
place. Store in a tightly closed container. Store at      
2-8
0 
 C. 
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4.3. EXCIPIENTS PROFILE 
4.2.1. METHACRYLIC ACID COPOLYMER
50,51 
 
Nonproprietary Names : BP: Methacrylic acid-ethyl acrylate copolymer (1:1).                                                            
PhEur: Acidum Methacrylicum et ethylis acrylas, 
Polymerisatum 1:1, Acidum methacrylicum ethylis 
arcylas polymersatum 1:1 dispersio 30 per centum.                                                              
USPNF: Ammonio methacrylate copolymer, 
methacrylic acid copolymer, methacrylic acid 
copolymer dispersion. 
 
Synonyms : Acryl-EZE, Acryl-EZE MP, Eastacryl 30D, protetab 
entric m1; bharth coat, polymeric methacrylic acid. 
 
Chemical Name                    :  Poly (methacrylic acid, ethyl acetate)1:1. 
 
Molecular Weight : About 2,50,000. 
 
Structural Formula  
 
Description    : Synthetic cationic and anionc polymers of dimethyl 
amino ethyl methacrylates, methacrylic acid, and 
methacrylic acid esters in varying ratio. 
 
Acid Value : 300-330. 
 
Density (Bulk)                       : 0.390 g/cm
3
. 
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Density (Tapped)                  : 0.424 g/cm
3
. 
 
Density (True)                       : 1.062-1.072 g/cm
3
. 
 
Solubility : Miscible in acetone and alcohols, 1N HCL , Petrolium 
ether. 
 
Viscosity (Dynamic)         : Dispersions are sensitive to extreme temperature and 
phase separation occurs below 0
o
c. Dispersions should 
therefore be stored at temperature between 5 to 25
o
c 
and are stable for at least 18 months after shipping 
from the manufactures warehouse if stored in a tightly 
closed container. 
 
Applications     : Poly methacrylates are primarily used in oral capsule 
and tablet formulations at film –coating agents. 
 
Incompatibilities :  Depends upon ionic and physical properties of the 
polymer and solvent. 
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4.2.2. METHYLENE DI CHLORIDE
52,53 
 
Chemical Name : Dichloromethane. 
 
Synonyms : F30, r30, R30, HCC30, CH2Cl2, Freon30, Nevolin, 
Driverit. 
 
Molecular Formula : CH2Cl2. 
 
Molecular weight : 84.93. 
 
Chemical structure :  
 
Melting point  : -97 °C. 
 
Boiling point  : 39.8-40 °C mm Hg (lit.) 
 
Vapour density  : 2.9  
 
 
Solubility 
 
: Miscible in ethyl acetate, alcohol, hexanes, 
methanol, diethyl ether, n-octanol, acetone. 
Description : Colorless, transparent, volatile liquid with pungent 
smell similar to ether. Soluble in water of about 50 
times the volume, soluble in phenol, aldehyde, 
ketone, acetic acid, triethyl phosphate, ethyl 
acetoacetate, cyclohexylamine. Miscibile with other 
chlorinated hydrocarbon, solvent ethanol 
 
Category : Pesticide. 
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Toxicity : Its oral toxicity is moderate. 
 
Uses 
 
: The most important use of dichloromethane is 
solvent. It is largely used in the manufacture of safe 
film, polycarbonate, the rest used as paint solvents, 
metal degreasing agent, gas aerosol spray, 
polyurethane foam, mold release agent, paint 
remover. It is also used as the reaction medium in 
the pharmaceutical industry for the preparation of 
ampicillin, ampicillin and cephalosporin. 
Dichloromethane is inert because of the 
stereoscopic electron effect, and usually does not 
participate in the chemical reaction. But under 
certain conditions it can also participate in the 
reaction. Explosion accident occurred in industry 
because of the generation of diazomethane methane 
when residual dichloromethane and sodium azide 
reacted in N, N-dimethyl formamide. 
Dichloromethane is mainly used in film production 
and medicine in China. Film production accounts 
for 50% of the total consumption, medicine 
accounts for 20%, the cleaning agent and chemical 
industry accounts for 20%, and others accounts for 
10%. 
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4.2.3. COPOVIDONE
52,53
 
 
Nonproprietary Names 
 
 
 
: BP: Copovidone. 
PhEur: Copovidone. 
USP-NF: Copovidone. 
 
Synonyms 
 
 
 
 
: Acetic acid vinyl ester, polymer with 1-vinyl-2-
pyrrolidinone; copolymer of 1-vinyl-2-pyrrolidone 
and vinyl acetate in a ratio of 3 : 2 by mass; 
copolyvidone; copovidonum; Kollidon VA 64; 
Luviskol VA; Plasdone S-630; poly(1-
vinylpyrrolidone-co-vinyl acetate); 
polyvinylpyrrolidone-vinyl acetate copolymer; 
PVP/VA; PVP/VA copolymer. 
 
Chemical Name : Acetic acid ethenyl ester, polymer with 1-ethenyl-2-
pyrrolidinone [25086-89-9] 
 
Embrical Formula and 
Molecular Weight 
: (C6H9NO)n . (C4H6O2)m (111.1)n. (86.1)m 
   
Structural Formula 
 
: 
 
 
Functional Category 
 
: 
 
Film-forming agent; granulation aid; tablet binder. 
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Description 
 
: Copovidone is a white to yellowish-white amorphous 
powder. It is typically spray-dried with a relatively 
fine particle size. It has a slight odor and a faint taste. 
 
Applications  : Copovidone is used as a tablet binder, a film-former, 
and as part of the matrix material used in controlled-
release formulations. In tableting, copovidone can be 
used as a binder for direct compression(1–3) and as a 
binder in wet granulation.(4,5) Copovidone is often 
added to coating solutions as a film-forming agent. It 
provides good adhesion, elasticity, and hardness, and 
can be used as a moisture barrier. 
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4.2.4. MAGNESIUM OXIDE
52,53
 
 
Nonproprietary Names 
 
: BP: Heavy Magnesium Oxide. 
Light Magnesium Oxide. 
JP: Magnesium Oxide. 
PhEur: Magnesium Oxide, Heavy 
Magnesium Oxide, Light. 
USP: Magnesium Oxide. 
 
 
Synonyms 
 
: Calcined magnesia; calcinated magnesite; Descote; 
E530; Magcal; Magchem 100; Maglite; magnesia; 
magnesia monoxide; magnesia usta; magnesii 
oxidum leve; magnesii oxidum ponderosum; 
Magnyox; Marmag; Oxymag; periclase. 
 
 
Chemical Name  : Magnesium oxide. 
 
 
Empirical Formula  : MgO. 
 
 
Molecular Weight 
 
: 40.30 
Structural Formula : MgO. 
 
 
Functional Category 
 
: Anticaking agent; emulsifying agent; glidant; tablet 
and capsule diluent. 
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Description 
 
: Fine, white, odorless amorphous powder. 
 
 
Applications 
 
: Magnesium oxide is used as an alkaline diluent in 
solid-dosage forms to modify the pH of tablets. It can 
be added to solid-dosage forms to bind excess water 
and keep the granulation dry. In combination with 
silica, magnesium oxide can be used as an auxiliary 
glidant. It is also used as a food additive and as an 
antacid, either alone or in conjunction with aluminum 
hydroxide. Magnesium oxide is additionally used as 
an osmotic laxative and a magnesium supplement to 
treat deficiency states. 
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4.2.5. MANNITOL ANHYDROUS
52,53 
Non-Proprietary Names : BP: Mannitol.  
JP: D-Mannitol. 
PhEur: Mannitol. 
USP: Mannitol.    
Synonyms : Cordycepic acid, Emprove, Manna sugar, 
D-mannite, Mannite, Mannitolum; 
Mannogem, Pearlitol.     
Chemical Name : D-Mannitol. 
Empirical Formula : C6H14O6. 
Molecular Structure : 
Molecular Weight : 182.17g/mol. 
Melting  Point : 166-168°C. 
Solubility : Soluble in alkalis and practically insoluble in 
ether. 
Description : Mannitol occurs as a white, odorless, 
crystalline powder or free-flowing granules. 
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Functional Category : Diluent, plasticizer, sweetening agent, tablet 
and capsule diluent, therapeutic agent and 
tonicity agent. 
Applications : Mannitol is widely used in Pharmaceutical 
formulations and food products. In 
pharmaceutical preparations it is primarily 
used as a diluent (10–90% w/w) in tablet 
formulations, where it is of particular value 
since it is not hygroscopic and may thus be 
used with moisture-sensitive active 
ingredients. Mannitol may be used in direct-
compression tablet applications, for which the 
granular and spray-dried forms are available 
or in wet granulations.  
Stability And Storage Conditions : Mannitol is stable in the dry state and in 
aqueous solutions. The bulk material should 
be stored in a well-closed container in a cool, 
dry place. 
Incompatibilities : Mannitol solutions, 20% w/v or stronger, may 
be salted out by potassium chloride or sodium 
chloride. Precipitation has been reported to 
occur when a 25% w/v mannitol solution was 
allowed to contact plastic. Mannitol was 
found to reduce the oral bioavailability of 
cimetidine compared to sucrose. 
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4.2.6. CROSPOVIDONE
52,53 
Non-Proprietary Names : BP: Crospovidone. 
PhEur: Crospovidonum. 
USPNF: Crospovidone. 
Synonyms : Crosslinkedpovidone, Kollidon CL, 
Kollidon CL-M, Polyplasdone XL, 
Polyvinylpolypyrrolidone. 
Chemical Name : 1-Ethenyl-2-pyrrolidinone homopolymer. 
Empirical Formula : (C6H9NO)n. 
Molecular Structure   : 
Molecular Weight : 2.5 g/mol. 
Melting  Point : 150
0
C. 
Solubility : Practically insoluble in water and most 
common organic solvents. 
Description : Crospovidone is a white to creamy-white, 
finely divided, free-flowing, practically 
tasteless, odorless or nearly odorless, 
hygroscopic powder. 
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Functional Category : Tablet disintegrant. 
Applications : Crospovidone is a water-insoluble tablet 
disintegrant and dissolution agent used at 
2–5% concentration in tablets prepared by 
direct-compression or wet- and dry-
granulation methods. It rapidly exhibits 
high capillary activity and pronounced 
hydration capacity, with little tendency to 
form gels. Crospovidone can also be used 
as a solubility enhancer. 
Stability And Storage 
Conditions 
: Crospovidone is hygroscopic; it should be 
stored in an airtight container in a cool, 
dry place. 
Incompatibilities : Crospovidone is compatible with most 
organic and inorganic Pharmaceutical 
ingredients. When exposed to a high water 
level, crospovidone may form molecular 
adduct with some materials.     
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4.2.7. METHYL PARABEN
52,53 
Non-Proprietary Names : BP: Methyl hydroxybenzoate. 
JP: Methyl parahydroxybenzoate. 
PhEur: Methylisparahydroxybenzoas. 
USPNF: Methylparaben. 
Synonyms : 4-hydroxybenzoic acid methyl ester, 
methyl p-hydroxybenzoate, Nipagin M.   
Chemical Name : Methyl-4-hydroxy benzoate. 
Empirical Formula : C8H8O3. 
Molecular Structure   : 
Molecular Weight : 152.15 g/mol. 
Melting  Point : 125–128
0
 C.
Solubility : Soluble in water when heated. 
Description : Methylparaben occurs as colorless crystals 
or a white crystalline powder. It is odorless 
or almost odorless and has a slight burning 
taste. 
CHAPTER 4             EXCIPIENTS PROFILE 
DEPARTMENT OF PHARMACEUTIC, S.B.C.P. Page 51 
Functional Category : Antimicrobial preservative.  
Applications : Methylparaben is widely used as an 
antimicrobial preservative in cosmetics, 
food products and Pharmaceutical 
formulations. 
Stability And Storage 
Conditions 
: Aqueous solutions of methyl paraben at pH 
3–6 may be sterilized by autoclaving at 
120
0
 C for 20 minutes, without 
decomposition. Methylparaben should be 
stored in a well-closed container in a cool, 
dry place. 
Incompatibilities : The antimicrobial activity of 
methylparaben and other parabens is 
considerably reduced in the presence of 
nonionic surfactants, such as 
polysorbate 80, as a result of micellization. 
Methylparaben is discolored in the 
presence of iron and is subject to 
hydrolysis by weak alkalis and strong 
acids. 
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4.2.8. PROPYL PARABEN
52,53
Non-Proprietary Names : BP: Propyl hydroxybenzoate. 
JP: Propyl parahydroxybenzoate. 
PhEur: Propylisparahydroxybenzoas. 
USPNF: Propylparaben. 
Synonyms : 4-hydroxybenzoic acid propyl ester, 
Nipasol M, Propyl p-hydroxybenzoate; 
Propyl parasept, Solbrol P. 
Chemical Name : Propyl 4-hydroxybenzoate. 
Empirical Formula : C10H12O3. 
Molecular Structure  : 
Molecular Weight : 180.20 g/mol. 
Melting  Point : 96-99
o
C.
Solubility : Soluble in water when heated. 
Description : Propylparaben occurs as a white, 
crystalline, odorless and tasteless powder. 
Functional Category : Antimicrobial preservative. 
CHAPTER 4             EXCIPIENTS PROFILE 
DEPARTMENT OF PHARMACEUTIC, S.B.C.P. Page 53 
Applications : Propylparaben is widely used as an 
antimicrobial preservative in cosmetics, 
food products. 
Stability And Storage 
Conditions 
: Propylparaben is stable under normal 
conditions. It decomposes on heating. 
Stored in a tightly closed container. 
Incompatibilities : The activity of propylparaben can be 
adversely affected by the presence of other 
excipients or active ingredients, such as 
atropine, essential oils, iron, magnesium 
trisilicate, talc, polysorbate and other 
nonionic surfactants, sorbitol, weak alkalis 
and strong acids.     
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4.2.9. MAGNESIUM STEARATE
52,53
Non-Proprietary Names : BP: Magnesium stearate. 
JP: Magnesium stearate. 
PhEur: Magnesiistearas. 
USPNF: Magnesium stearate. 
Synonyms : Magnesium octadecanoate, Octadecanoic 
acid, Magnesium salt, Stearic acid and 
Magnesium salt. 
Chemical Name : Octadecanoic acid magnesium salt. 
Empirical Formula : C36H70MgO4. 
Molecular Structure   : 
Molecular Weight : 591.34 g/mol. 
Melting  Point : 117-150
0
C.
Solubility : Practically insoluble in ethanol, ether and 
water, slightly soluble in warm benzene 
and warm ethanol. 
Description : Magnesium stearate is a very fine, light 
white, precipitated or milled, impalpable 
powder of low bulk density, having a faint 
odor of stearic acid and a characteristic 
taste. 
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Functional Category : Tablet and capsule lubricant. 
Applications : Magnesium stearate is widely used in 
cosmetics, foods and Pharmaceutical 
formulations. It is primarily used as a 
lubricant in capsule and tablet manufacture 
at a concentration between 0.25% and 
5.0% w/w. It is also used in barrier creams. 
Stability And Storage Conditions : Magnesium stearate is stored in a well 
closed container in a cool dry place. 
Incompatibilities : It incompatible with strong acids, alkalis 
and iron salts. It cannot be used be used in 
products containing aspirin, vitamins and 
alkalodial salts.     
CHAPTER 4             EXCIPIENTS PROFILE 
DEPARTMENT OF PHARMACEUTIC, S.B.C.P. Page 56 
4.2.10. LAKE IRON OXIDE RED
52,53 
Nonproprietary Names : None adopted. 
Synonyms : Iron oxide yellow monohydrate: E172; hydrated 
ferric oxide; iron (III) oxide monohydrate, 
yellow; pigment yellow 42; yellow ferric oxide. 
Iron (III) oxide hydrated: Bayferrox 920Z; CI 
77492; ferric hydroxide; ferric hydroxide oxide; 
ferric hydrate; ferric oxide hydrated; Ferroxide 
510P; iron hydrate; iron hydroxide; iron 
hydroxide oxide; Mapico Yellow EC; Sicovit 
Y10; yellow ochre; yellow iron oxide. 
Chemical Name And CAS 
Registry Number 
: Iron oxide red [51274-00-1] (monohydrate); 
[20344- 49-4] (hydrate) 
Empirical Formula And 
Molecular Weight 
: Fe2O3H2O - 88.85 
Structural Formula : Iron oxides are defined as inorganic compounds 
consisting of any one of or combinations of 
synthetically prepared iron oxides, including the 
hydrated forms. 
Functional Category : Colorant. 
Description : Iron oxides occur as yellow, red, black, or brown 
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powder. The color depends on the particle size 
and shape, and crystal structure.
Solubility : Soluble in mineral acids; insoluble in water. 
Applications : Applications in Pharmaceutical Formulation or 
Technology Iron oxides are widely used in 
cosmetics, foods, and pharmaceutical 
applications as colorants and UV absorbers. As 
inorganic colorants they are becoming of 
increasing importance as a result of the 
limitations affecting some synthetic organic 
dyestuffs. However, iron oxides also have 
restrictions in some countries on the quantities 
that may be consumed, and technically their use 
is restricted because of their limited color range 
and their abrasiveness. 
Stability And Storage 
Conditions 
: Iron oxides should be stored in well-closed 
containers in a cool, dry place. 
Incompatibilities : Iron oxides have been reported to make hard 
gelatin capsules brittle at higher temperatures 
when the residual moisture is 11–12%. This 
factor affects the use of iron oxides for coloring 
hard gelatin capsules, and will limit the amount 
that can be incorporated into the gelatin material. 
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4.2.11. ISOPROPYL ALCOHOL
52,53
Nonproprietary Names : BP: Isopropyl Alcohol 
JP: Isopropanol 
PhEur: Isopropyl Alcohol 
USP: Isopropyl Alcohol 
Synonyms : Alcohol isopropylicus; dimethyl carbinol; IPA; 
isopropanol; petrohol; 2-propanol; sec-propyl 
alcohol; rubbing alcohol. 3 Chemical Name and 
CAS Registry Number Propan-2-ol [67-63-0] 
Empirical Formula : C3H8O. 
Molecular Weight : 60.1. 
Structural Formula : 
Functional Category : Disinfectant, solvent. 
Description : Isopropyl alcohol is a clear, colorless, mobile, 
volatile, flammable liquid with a characteristic, 
spirituous odor resembling that of a mixture of 
ethanol and acetone; it has a slightly bitter taste. 
CHAPTER 4             EXCIPIENTS PROFILE 
DEPARTMENT OF PHARMACEUTIC, S.B.C.P. Page 59 
Solubility : Miscible with benzene, chloroform, ethanol 
(95%), ether, glycerin, and water. Soluble in 
acetone; insoluble in salt. 
Stability and Storage Conditions : Isopropyl alcohol should be stored in an airtight 
container in a cool, dry place. 
Incompatibilities : Incompatible with oxidizing agents such as 
hydrogen peroxide and nitric acid, which cause 
decomposition. Isopropyl alcohol may be salted 
out from aqueous mixtures by the addition of 
sodium chloride, sodium sulfate, and other salts, 
or by the addition of sodium hydroxide. 
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4.4 LIST OF EQUIPMENTS 
Table 2:   LIST OF EQUIPMENTS AND THEIR MANUFACTURERS. 
 
S.No Instruments Manufacturers 
1 Single pan electronic balance Sartorious,Germany 
2 
12 Station D/B Tooling compression 
Machine 
Fluid pack, Ahmedabad,India 
3 R&D Mini coater Ideal cure pvt ltd ,Mumbai, India 
4 Vernier calipers Mitutoyo, Japan 
5 Dissolution Test Apparatus Electro Lab, Mumbai, India 
6 Hardness Tester Monsanto,Mumbai,India 
7 Friability Test Apparatus Electro Lab, Mumbai, India 
8 Sieves Jayant Scientific Ind, Mumbai,India 
9 Disintegration Test Apparatus Electro Lab, Mumbai, India 
10 FTIR Shimadzu, Japan 
11 HPLC Waters, USA 
12 Stability Chamber Labtop, Mumbai, India 
13 Blister Packing Machine 
Elmach packages pvt  ltd, Mumbai, 
India 
 
 
 
  
 
 
 
 
METHODOLOGY 
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4.5. METHODOLOGY 
4.4.1. PREFORMULAION STUDY
54 
Preformulation studies are designed to determine the compatibility of initial 
excipients with the active substance for a biopharmaceutical, physicochemical and analytical 
investigation in support of promising experimental formulations. Successful formulations 
take into account a drug’s interactions with the physicochemical properties of other 
ingredients [and their interactions with each other] to produce a safe, stable, beneficial and 
marketed product. The basic purpose of the preformulation activity are to provide a rational 
basis for the formulation approaches, to maximize the chances of success in formulating an 
acceptable product and to ultimately provide a basis for optimizing drug product quality and 
performance. The first step in any formulation activity is careful consideration of a complete 
physicochemical profile of the active ingredients available prior to initiating a formulation 
development activity. 
4.4.1.1. DESCRIPTION 
It is the initial evaluation during preformulation studies which assess the colour and 
taste of the substance. This was only a descriptive test. 
 
4.4.1.2. SOLUBILITY
55
 
Aqueous solubility is an important physicochemical property of drug substance, 
which determines its systemic absorption and in turns its therapeutic efficacy.  
 
Table No.3: Solubility Specifications 
Descriptive terms Approximate volume of solvent 
in milliliters per gram  of solute 
Very soluble Less than 1 
Freely soluble From 1 to 10 
Soluble From 10 to 30 
Sparingly soluble From 30 to 100 
Slightly soluble From 100 to 1000 
Very slightly soluble From 1000 to 10,000 
Practically insoluble More than 10,000 
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4.4.1.3. DRUG EXCIPIENT COMPATIBILITY STUDY 
The tablet dosage form the drug is in intimate contact with one or more excipients, the 
latter could affect the stability of the drug. Knowledge of drug-excipients interactions 
therefore is very useful to the formulators in selecting appropriate excipients. This 
information may already be in existence for known drug.  
Method 
Compatibility was performed by preparing compatibility blends at different ratio of different 
excipients with API, based on the tentative average weight. The blends were stored at 
accelerated condition of 40°C ±2°C/ 75% ±5% RH for 30 days. The samples were compared 
with initial samples data after the 2
nd
 and 4
th
 week of the study. 
 
Table No.4: Drug excipients compatibility study 
 
4.4.1.4.  DRUG – EXCIPIENT INTERACTION STUDIES BY FT-IR 
Infra red spectra matching approach was used for the detection of any possible 
chemical reaction between the drug and the excipients.  A physical mixture (1:1) of drug and 
excipients was prepared and mixed with suitable quantity of potassium bromide. About 100 
mg of this mixture was compressed to form a transparent pellet using a hydraulic press at 10 
tones pressure.  It was scanned from 4000 to 150 cm
-1 
in a shimadzu FTIR 
spectrophotometer.  The IR spectrum of the physical mixture was compared with those of 
pure drug and excipients and matching was done to detect any appearance or disappearance 
of peaks.  
S. No. Composition 
Ratio 
(Drug : Excipient) 
1 Rabeprazole sodium   - 
2 Rabeprazole sodium  + Mannitol anhydrous 1:1 
3 Rabeprazole sodium  + Copovidone 1:1 
4 Rabeprazole sodium  + Crospovidone 1:1 
5 Rabeprazole sodium  + Light magnesium oxide 1:1 
6 Rabeprazole sodium  + Methylparaben 1:1 
7 Rabeprazole sodium  + Propylparaben 1:1 
8 Rabeprazole sodium  + Magnesium stearate 1:1 
9 Rabeprazole sodium  + Instacoat moist shield white 1:1 
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4.4.2. FORMULATION OF RABEPRAZOLE SODIUM UNCOATED TABLETS   
Delayed release tablets of Rabeprazole sodium (20 mg) were prepared through direct 
compression method as per the composition shown in Table: The formulation codes, F-I to F-
VII, were prepared by direct compression method. Various steps (sieving, dry mixing, 
lubrication and compression) involved in the tablet production by direct compression method 
were mentioned below. 
Sieving 
The active ingredient was passed through the sieve # 40 followed by the other 
ingredients (details of the formulation codes F-I to F-VII in Table: were passed through the 
same sieve.  
Dry mixing        
All the materials (including the active ingredient) were taken in poly bag and mixed 
for 10 minutes for uniform mixing. 
Lubrication  
The magnesium stearate and talc were passed through the sieve # 60 and mixed 
together with the powder mixture in a polybag for 5 minutes to get a uniform blend. 
Compression  
Finally, the powder mixture was compressed into tablets using 7.14 mm round shape 
punches and dies, by using single rotary tablet compression machine. 
Packing Details 
The prepared tablets were packed with following specification: 10 tablets were 
packed in Alu-Alu Blister packing. 
 
4.4.3. COATING FORMULA 
Seal Coating 
 Accurately weighed ethyl cellulose and dissolved in acetone and milled for 20 
minutes. 
Moisture Prior Coating 
 The solid material of insta coat moisture shield white was dissolved in isopropyl 
alcohol and then mixed with methylene dichloride. Milled for 30 minutes. 
Enteric Coating 
 Protectab enteric M1 barath coat (methacrylic acid co polymer) powder was mixed 
with isopropyl alcohol. Iron oxide red was added to this solution. 
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Table No. 5: Composition of Rabeprazole Sodium Delayed Release Tablets 
 
Ingredients 
Quantity per tablet (mg) 
F-I F-II F-III F-IV F-V F-VI F-VII 
Rabeprazole sodium   20 20 20 20 20 20 20 
Mannitol anhydrous 173 169 165 161 161 161 161 
Copovidone - 4.00 4.00 4.00 4.00 4.00 4.00 
Crospovidone - - 4.00 8.00 8.00 8.00 8.00 
Light magnesium oxide 4.00 4.00 4.00 4.00 4.00 4.00 4.00 
Methylparaben 0.80 0.80 0.80 0.80 0.80 0.80 0.80 
Propylparaben 0.20 0.20 0.20 0.20 0.20 0.20 0.20 
Magnesium stearate 2.00 2.00 2.00 2.00 2.00 2.00 2.00 
Average weight of the  
un coated tablets 
200 200 200 200 200 200 200 
Seal coating 
Instacoat moist shield 
white 
- - - 3.80 3.80 3.80 3.80 
Isopropyl alcohol - - - 25.00 25.00 25.00 25.00 
Methylene dichloride - - - 50.00 50.00 50.00 50.00 
Lake of  iron oxide red - - - 0.20 0.20 0.20 0.20 
Enteric coating 
Protectab Enteric M1  - - - 4.80 9.80 14.80 19.80 
Isopropyl alcohol - - - 25.50 51.00 76.50 102.00 
Methylene dichloride - - - 25.50 51.00 76.50 102.00 
Lake of Ironoxide red - - - 0.20 0.20 0.20 0.20 
Polish coating 
Insta coat glow - - - 1.00 1.00 1.00 1.00 
Isopropyl alcohol - - - 3.50 3.50 3.50 3.50 
Methylene dichloride - - - 3.50 3.50 3.50 3.50 
Average weight of the  
Enteric coated tablets 
- - - 210.00 215.00 220.00 225.00 
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Coating parameters 
 
Table No. 6: Coating Parameters 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.4.4. EVALUATION OF PRECOMPRESSION PARAMETERS 
Angle of repose
56 
The angle of repose of API powder was determined by the funnel method. The 
accurately weight powder blend were taken in the funnel. The height of the funnel was 
adjusted in such a way the tip of the funnel just touched the apex of the powder blend. The 
powder blend was allowed to flow through the funnel freely on to the surface. The diameter 
of the powder cone was measured and angle of repose was calculated using the following 
equation. 
 
tan θ = h/r 
Where,  
h = Height of the powder cone. 
R = Radius of the powder cone. 
 
 
 
 
 
Specifications Enteric  coating range 
Pan diameter 12 
Speed of pan revolution 10-12 rpm 
Distance of spray gun 5-6 
Spray nozzle diameter 1.2 mm 
Spray rate 1.5 -2.0 ml /min 
Dry air temperature 50  ± 5
0
C / 30 mins 
Coating time 4 hours 
Bed temperature 30-40
0
C 
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Table No. 7: Flow properties and corresponding angle of repose 
 
Flow property  Angle of repose 
Excellent 25-30 
Good  31-35 
Fair 36-40 
Passaple 41-45 
Poor 46-55 
Very poor 56-65 
Very very poor >66 
 
 
Bulk density and tapped density
56,57 
Both Bulk density (BD) and tapped density (BD) was determined. A quantity of 2 gm 
of API powder from each formula, previously shaken to break any agglomerates formed, was 
introduced in to 10 ml measuring cylinder. After that the initial volume was noted and the 
cylinder was allowed to fall under its own weight on to a hard surface from the height of 2.5 
cm at second intervals. Tapping was continued until no further change in volume was noted. 
LBD and TDB were calculated using the following equations. 
 
Compressibility index
58 
Based on the apparent bulk density and the tapped density, the percentage 
compressibility of the bulk drug was determined by using the following formula. 
 
Compressibility index(%)  =  [
𝑻𝑫 – 𝑩𝑫
𝑻𝑫
 ] × 𝟏𝟎𝟎 
 
BD= Weight of the powder blend/Untapped Volume of the packing 
TD= Weight of the powder blend/Tapped Volume of the packing  
 
Hausner’s ratio59 
 The Hausner’s ratio is a number that is correlated to the flowability of a powder or 
granular material. Hausner’s ratio was calculated from the bulk and tapped density using the 
following formula,  
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Hausner’s ratio = 
𝑻𝒂𝒑𝒑𝒆𝒅 𝒅𝒆𝒏𝒔𝒊𝒕𝒚
𝑩𝒖𝒍𝒌 𝒅𝒆𝒏𝒔𝒊𝒕𝒚
 
 
Table No. 8: Scale of flowability 
 
Flow character Compressibility index 
(%) 
Hausner’s ratio 
Excellent <10 1.00 – 1.11 
Good 11 – 15 1.12 – 1.18 
Fair 16 – 20 1.19 – 1.25 
Passable 21 – 25 1.26 – 1.34 
Poor 26 – 31 1.35 – 1.45 
Very poor 32 – 37 1.46 – 1.59 
Extremely poor >38 >1.60 
 
 
4.4.5. EVALUATION OF POST COMPRESSION PARAMETERS 
The compressed tablets were evaluated for the following parameters. 
General appearence 
 The formulated tablets color, shape and dimension were measured through 
organoleptic testing methods and the same is reported in table:  
 
Hardness
60 
Tablet requires a certain amount of mechanical strength to withstand the shock of 
handling in its manufacture, packaging, shipping and dispensing.  It may be especially 
important to monitor the tablet hardness for sustained release drug products or other products 
that possess real or potential bioavailability problems or sensitive to variations in drug release 
profile.  
The crushing strength that just causes the tablet to break is recorded by means of 
Monsanto hardness tester.  The tablet is placed vertically in between the lower and upper 
plungers.  The initial reading was taken immediately after placing the tablet onto the lower 
plunger. The upper plunger was then forced against a spring by turning a threaded bolt until 
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the tablet fractured. As the spring was compressed, a point moves along a gauge in the barrel 
to indicate pressure.   
 
Thickness
61 
Once the tablet size and shape have been established, tablet thickness remains the 
only overall dimensional variable.  Thickness should be controlled within 5% or less of an 
established standard value.  Excessive variation in tablet thickness can result in problems 
with packaging as well as consumer acceptance.  Variation in tablet thickness can also 
indicate force.  The thickness of the individual tablets was measured with vernier caliper. 
 
Weight Variation
62 
The weight variation test of the tablets was done as per the guidelines of Indian 
Pharmacopoeia. 20 tablets were selected at random and its individual weight was noted and 
from then, the mean weight of the tablet was calculated. Percentage deviation of each tablet 
from the mean was determined Table No. 7:  
 
Table No. 9: Percentage Deviation of Tablets 
S. No. 
Average weight of tablet 
(mg)  
Percentage  deviation 
1 130 or less ± 10.0 
2 130-324  ± 7.5 
3 More than 324 ± 5.0 
 
Not more than 2 of the individual weights deviate from the average weight by more 
than 5% and none deviates by more than twice that percentage. 
 
Friability
63 
Friability is the measure of a tablet’s ability to withstand both shock and abrasion 
without crumbling during the handling of manufacturing, packing, shipping and consumer 
use. Tablets that tend to powder, chip, and fragment when handled lack elegance, and hence, 
consumer acceptance.  The weight of 10 tablets was noted and placed them in Roche type 
friabilator. The device subjects the tablets to the combined effect of shock and abrasion by 
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utilizing a plastic chamber which revolves at 25 rpm, rolling the tablets a distance of 6 inches 
with the revolution. The pre-weighed tablet sample is removed after 100 revolutions, dusted 
and reweighed. Tablets that loose less than 0.5 to 1 percent in weight are generally 
considered acceptable.  
 
Disintegration test 
The disintegration test was carried out according to IP procedure on six tablets using 
disintegration test apparatus with discs in 0.1N HCL (pH 1.2) maintained at 37°C ± 2°C for 2 
hours. After 2 hours 0.1N HCL was replaced with phosphate buffer 6.8 pH. A disc was added 
to each tube and operated for further 60 minutes. The disintegration time of each tablet was 
recorded. 
 
Drug Content Determination by UV
64 
Solvent preparation 
 Methanol:Purified water (80:20). 300 ml methanol added into 700 ml of 
purified water to make 1000 ml of diluent. 
Sample Preparation  
Accurately weighed crushed tablet power equivalent 100mg of Rabeprazole sodium 
was placed into a clean 100 ml volumetric flask and 50 ml of diluents was added. Mixed well 
and sonicated for 20 minutes. Then make up to 100 ml with diluents. Filtered and diluted 1 
ml to 100 ml and from this, 5 ml was diluted to 10 ml. 
Standard preparation  
Accurately weighed 100 mg of Rabeprazole sodium working standard in a clean, 100 
ml volumetric flask and dissolved into 50 ml of diluents. The volume was making up to 100 
ml with diluents. 1 ml of this solution was diluted to 100 ml with diluents. From this, 5 ml of 
the resulting solution was diluted to 10 ml with diluents. 
Procedure 
The absorbance of both the standard and sample preparations was measured at 284 
nm using diluents as a blank. The drug content of prednisolone present per tablet was 
calculated by using the following expression. 
 
 CHAPTER 4                                                                                                                          MATERIALS AND METHODS 
 
DEPARTENT OF PHARMACEUTICS, S.B.C.P Page 70 
 
𝐷𝑟𝑢𝑔 𝑐𝑜𝑛𝑡𝑒𝑛𝑡 =
𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓𝑠𝑎𝑚𝑝𝑙𝑒
𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑
×
𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑
100
 ×
1
100
×
5
10
      
×
100
𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒 
×
100
1
×
10
5
×
𝑝𝑢𝑟𝑖𝑡𝑦 𝑜𝑡 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑
𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑤𝑒𝑖𝑔ℎ𝑡
 × 100 
 
𝐴𝑠𝑠𝑎𝑦 =
𝑑𝑟𝑢𝑔 𝑐𝑜𝑛𝑡𝑒𝑛𝑡
𝑙𝑎𝑏𝑒𝑙 𝑐𝑙𝑎𝑖𝑚
× 100 
 
 
In vitro Drug Release Studies
65 
Drug release studies were carried out using a USP type II paddle dissolution test 
apparatus at 50 rpm for 2 hr in 0.1 N HCl (900 ml) maintained at 37°C ± 0.5°C. 10 ml of 
sample was taken and sample was analyzed using UV spectrophotometer at 284 nm. Then the 
dissolution medium was replaced with pH 7.4 phosphate buffer (900 ml) and tested for drug 
release for 45 minutes at 37°C ± 0.5°C temperature and 75 rpm speed. After 10, 20, 30 and 
45 minutes, 10 ml of the samples were taken out and 10 ml Volume of fresh phosphate buffer 
pH 7.4 was added to kept volume of dissolution medium constant and sample was analyzed 
using UV spectrophotometer 284 nm. 
 
STABILITY STUDIES OF THE TABLETS
66,67,68
 
Stability of a formulation can be defined as the time from date on manufacture of the 
formulation until its chemical or biological activity is not less than a predetermined level of 
labeled potency and its physical characteristics have not changed appreciably or 
deleteriously.   
 
 Formulation and the development of a pharmaceutical product is not complete 
without proper stability analysis, carried out on it to assess the physical and chemical stability 
and the safety.  The purpose of stability testing is to provide evidence on how the quality of a 
drug substance of drug product varies with time.  Under the influence of a variety of 
environmental factors such as temperature, humidity and light, enabling recommended 
storage conditions, re-test periods and shelf lives. 
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 Generally, the observation of the rate at which the product degrades under normal 
room temperature requires a long time. To avoid the undesirable delay, the principles of 
accelerated stability studies are adopted.  
 
 The International Conference on Harmonization (ICH) Guidelines titled “Stability 
testing of new drug substances and product” (QIA) describes the stability test requirements 
for drug registration application in the European Union, Japan and United States of America. 
ICH specifies the length of study and storage conditions.   
 
 Long –term testing: 25  2°C/60%   5% RH for 12 months. 
 Accelerated testing: 40  2°C/75%   5% RH for 6 months. 
 
Stability studies was carried out at 25°C/60% RH and 40°C/75% RH for optimized 
formulation (F-VII) for 12 weeks.  
 
Method 
The selected clear Alu-Alu packed formulations stored at 25°C/ 60% RH and 
40°C/75% RH for 3 months and evaluated for their physical appearance and drug content at 
specified intervals of  every month. The formulations were further scanned to observe any 
possible spectral changes. 
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5. RESULTS AND DISCUSSION 
 
5.1. PREFORMULATION STUDIES  
 
5.1.1. DESCRIPTION  
 
Table No. 10: Description of Rabeprazole Sodium 
S. No. Tests Results 
1 Colour White 
2 Odour Unpleasant  
3 Nature Crystalline 
4 Taste Bitter 
 
Discussion:  
The colour, odour, nature and taste of the API were evaluated. It was found to be as 
per the monograph. 
 
5.1.2. SOLUBILITY 
Table No. 11 Solubility of drug 
 
Discussion:  
 
Thus the results revealed that the drug was soluble in water, methanol and ethanol. 
 
 
 
 
 
 
Raw material Solubility 
Rabeprazole sodium 
Soluble in water, 
Soluble in  methanol 
Soluble in  ethanol 
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5.1.3. DRUG - EXCIPIENT COMPATIBILITY STUDY 
 
Table No. 12: Drug Excipients Compatibility Study 
 
 
Note: NCC – No Characteristic change 
 
Discussion: 
From the drug excipients compatibility study, it was observed that there was no 
change between drug and excipients. Thus it was concluded that the excipients selected for 
the formulation were compatible with Rabeprazole sodium. 
 
S. No. Composition 
Description 
INITIAL 
PERIOD 
2
nd
 
WEEK 
4
th
 
WEEK 
1 Rabeprazole sodium   white to off 
white powder 
NCC NCC 
2 Rabeprazole sodium  + Mannitol 
anhydrous 
white to off 
white powder 
NCC NCC 
3 Rabeprazole sodium  + Copovidone white to off 
white powder 
NCC NCC 
4 Rabeprazole sodium  + 
Crospovidone 
white to off 
white powder 
NCC NCC 
5 Rabeprazole sodium  + Light 
magnesium oxide 
white to off 
white powder 
NCC NCC 
6 Rabeprazole sodium  + 
Methylparaben 
white to off 
white powder 
NCC NCC 
7 Rabeprazole sodium  + 
Propylparaben 
white to off 
white powder 
NCC NCC 
8 Rabeprazole sodium  + Magnesium 
stearate 
white to off 
white powder 
NCC NCC 
9 Rabeprazole sodium  + Instacoat 
moist shield white 
white to off 
white powder 
NCC NCC 
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5.1.4. COMPATIBILITY STUDIES BY FT-IR 
 
 
 
Figure 3: FTIR Spectra of Rabeprazole Sodium 
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FTIR Spectral Data of Rabeprazole Sodium 
Table no.13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S. No Wave Number (cm
-1
) Functional Group 
1. 1083 N-H Bending of  Primary Amines 
2. 1298 
N-O Symmetric stretching of Nitro 
compounds 
3. 1460 C-N Stretching 
4. 1583 C-C Stretching of Benzene 
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Figure 4: FTIR Spectra of Rabeprazole Sodium Enteric Coated Tablets 
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FTIR Spectral Data of Rabeprazole Sodium Enteric Coated Tablets 
 Table no.14 
 
 
 
 
Discussion: 
 In FTIR spectra the peaks of physical mixture were compared with the 
Pharmacopoeia reference spectra. Same peaks were observed, indicates no possible molecular 
interaction between the drug and the Excipients. 
 
 
 
 
 
 
 
 
 
 
S. No Wave Number (cm
-1
) Functional Group 
1. 1080 N-H Bending of  Primary Amines 
2. 1298 
N-O Symmetric stretching of Nitro 
compounds 
3. 1456 C-N Stretching 
4. 1583 C-C Stretching of Benzene 
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5.2. EVALUATION OF PRECOMPRESSION PARAMETERS 
 
Table No. 15: Precompression Parameters of Rabeprazole Sodium Powder 
  
Formulation 
Code 
Angle of 
Repose 
(θ) 
 
Bulk 
Density  
(g/ml) 
Tapped 
Density  
(g/ml) 
Compressibility 
index (%) 
Hausner’s 
ratio 
F-I  27.9±0.3 0.31±0.1 0.37±0.3 16.0±0.1 1.19±0.3 
F-II 29.9±0.3 0.31±0.3 0.37±0.1 15.8±0.3 1.19±0.2 
F-III 24.0±0.2 0.31±0.1 0.37±0.4 15.1±0.6 1.19±0.2 
F-IV  29.5±0.1 0.31±0.2 0.36±0.1 16.5±0.2 1.16±0.1 
F-V 27.6±0.4 0.32±0.2 0.37±0.2 15.5±0.7 1.15±0.2 
F-VI 26.1±0.3 0.32±0.1 0.37±0.4 15.3±0.5 1.15±03 
F-VII 25.0±0.2 0.31±0.4 0.36±0.2 15.85±0.3 1.16±0.2 
 
* All the values are expressed as mean ± SD; n=3. 
Discussion: 
 The angle of repose was found to be in the range of 24.0 ± 0.2 to 29.9 ± 0.3 for all 
formulations. If the angle of repose was within 30
o
, it shows excellent flow properties. The 
result proved that all the formulations showed excellent flow properties. 
 The bulk density of all formulations was measured by using bulk density apparatus. 
The bulk density was in the range 0.31 ± 0.1 to 0.32 ± 0.2 g/cm
3
. 
 The tapped density of all formulations was measured by using tapped density 
apparatus. The tapped density was found in the range of 0.36 ± 0.1 to 0.37 ± 0.3 g/cm
3
. 
 The compressibility index was in the range of 15.1 ± 0.6 to 16.5 ± 0.2 %. It proved 
that the flow behaviours and compressibility of the granules are good. The hausner’s ratio lies 
in the range of 1.15 ± 0.2 to 1.19 ± 0.3. Hence the flow properties of all formulations were 
good. 
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5.3. EVALUATION OF POST COMPRESSION PARAMETERS 
 
Table No.16: Evaluation of Rabeprazole sodium Uncoated Tablets 
Formulation 
Code 
Average  
Thickness 
(mm) 
 
Hardness 
(kg /cm
2
) 
 
Weight 
Variation 
(%) 
Friability 
(%) 
Drug 
Content (%) 
F-I 3.32± 0.042 7.50± 0.32 202±1.42 0.01±0.002 100.50±1.30 
F-II 3.30± 0.014 7.20± 0.29 200±1.39 0.06±0.001 99.32±2.69 
F-III 3.28± 0.030 7.00± 0.27 201±2.78 0.28±0.001 98.65±3.05 
F-IV 3.38 ± 0.022 7.60± 0.49 205±0.19 0.46±0.003 101.96±1.78 
F-V 3.42 ± 0.020 7.10± 0.24 200±3.10 0.32±0.005 100.72±1.39 
F-VI 3.30± 0.054 7.50± 0.21 202±1.90 0.20±0.002 99.21±2.87 
F-VII 3.40± 0.020 7.50± 0.22 201±2.30 0.15±0.004 102.63±2.51 
 
* All the values are expressed as mean ± SD; n=3. 
  
Discussion: 
General Appearance 
 The formulated tablets were evaluated for their organoleptic characters. The tablets 
are round in shape and red in colour. All the tablets showed elegance in appearance. 
 
Thickness 
 Thickness of the tablets was found to be in the range of 3.28 ± 0.030 mm to            
3.42 ± 0.020 mm. The results showed that the thickness of all formulated tablets was found to 
be uniform. 
 
Hardness 
 The hardness of the tablets was measured by Monsonto hardness tester. The hardness 
of all the formulations was found to be in the range of 7.00 ± 0.27 to 7.60 ± 0.49 kg/cm
2
. It 
indicates all the tablets have adequate mechanical strength. 
CHAPTER 5  RESULTS AND DISCUSSION
DEPARTMENT OF PHARMACEUTICS, S.B.C.P. Page 80 
Weight variation test 
Twenty tablets of each formulation were selected for weight variation test. The 
accepted percentage deviation was ±7.5 for 130-324mg weight tablets. The results showed 
that weight variation was ranging from 200 ± 1.39 to 205 ± 0.19mg. It was within the I.P. 
limit and all the tablets passed the weight variation test. 
Friability test 
Friability test was carried out by Roche friabilitor. The maximum weight loss should 
be not more than 1%. The maximum and minimum friability values among 7 formulations 
were found to be in the range of 0.01 ± 0.002 to 0.46 ± 0.003% respectively. Hence all the 
tablets passed the friability test. 
Drug content 
The assay of Rabeprazole sodium delayed release tablets were found in the range 
between 98.65±3.05 and 102.63±2.51. The acceptable limit of Rabeprazole sodium content as 
per I.P. is 90 to 110%. The results revealed that the assay of Rabeprazole sodium was within 
the acceptable limits. 
5.4. EVALUATION OF COATED TABLETS 
Table No. 17:  Evaluation of Rabeprazole sodium Delayed Release Tablets. 
Formulation 
Code 
Thickness 
(mm) 
Weight 
Variation 
(%) 
Disintegration test 
Drug Content 
(%) Acid medium 
(mins) 
Buffer medium 
Mins / sec 
F-IV 3.50 ± 0.032 211.05±0.19 35 - 101.96±1.78 
F-V 3.58 ± 0.071 214.86±3.10 75 - 100.72±1.39 
F-VI 3.65± 0.046 221.34±1.90 103 - 99.86±2.87 
F-VII 3.72± 0.026 225.57±2.30 120 10.50’’ 102.63±2.51 
Marketed 
sample 
2.90± 0.055 210.00±2.50 120 15.20’’ 99.02±1.65 
* All the values are expressed as mean ± SD; n=3.
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Discussion: 
In F-IV to F-VI formulations, the disintegration time in acid medium was found to be 
35, 75 and 103 minutes. It was not within the limit. The disintegration time for F-VII 
formulation in acid medium was found to be within the limit. When compared with marketed 
sample, it showed better disintegration time. 
5.5. IN VITRO DRUG RELEASE STUDIES 
Table No. 18: In vitro Drug Release of Rabeprazole sodium Delayed Release Tablets 
Dissolution 
media 
Sampling 
time 
% Drug release 
F-IV F-V F-VI F-VII 
Marketed 
sample 
(0.1 N HCl) 2 hrs 2.57± 0.67 2.08± 0.12 1.8± 0.12 1.6 ± 0.50 1.7 ± 0.58 
(6.8pH 
Phosphate 
buffer) 
5 mins 4.89± 0.38 2.44± 0.43 6.2± 0.67 7.34 ± 0.33 7.10 ± 0.12 
10 mins 7.5± 0.12 5.10± 0.43 14.23± 0.14 19.77 ± 0.67 18.25 ± 0.24 
15 mins 28.22± 0.14 29.45± 0.21 30.32± 0.22 40.37 ± 0.58 39.45 ± 0.36 
20 mins 32.54± 0.67 34.23± 0.58 52.22± 0.12 75.28 ± 0.38 73.32 ± 0.14 
30 mins 40.22± 0.58 46.06± 0.43 72.32± 0.12 87.19 ± 0.22 85.56 ± 0.43 
45 mins 44.62± 0.12 59.62 ± 0.43 86.21± 0.36 99.98 ± 0.12 98.68 ± 0.21 
* All the values are expressed as mean ± SD; n=3.
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Figure 5: Comparative Dissolution Profile Study of Rabeprazole sodium Delayed 
Release Tablets 
Discussion: 
The results revealed that the drug released from marketed product was fairly matching 
with the drug release from Rabeprazole sodium delayed release tablet formulation F-VII. 
Based on this, F-VII was selected as best formulation other than F-IV,F-V,F-VI and subjected 
for stability studies. 
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5.6. STABILITY STUDIES 
 
Table No. 19: Stability studies for F-VII Rabeprazole sodium Delayed Release Tablets 
 
Parameters 
40
o
C ± 2
o
C/ 75% RH ± 5%RH 
Initial Period 1
st
 Month 2
nd
 Month 3
rd
 Month 
Description Round shaped 
red colour 
Round shaped 
red colour 
Round shaped 
red colour 
Round shaped 
red colour 
Average weight 
(mg) 
225.57±2.30 226.48 ± 2.13 226.89 ± 1.98 227.02 ± 1.84 
Hardness 
(kg/cm
2
) 
7.50± 0.22 7.48 ± 0.23 7.45 ± 0.20 7.43 ± 0.41 
Thickness (mm) 3.72± 0.02 3.71 ±0.02 3.68 ± 0.2 3.68 ± 0.08 
Disintegration 
time (mins) 
 
130.50’’ 
 
131.34’’ 
 
131.57’’ 
 
132.14’’ 
Assay (%) 102.63±2.51 101.98 ± 2.14 101.56 ± 2.04 101.13 ± 1.34 
* All the values are expressed as mean ± SD; n=3. 
 
Discussion: 
F-VII formulation was kept for stability studies. No physical changes were observed 
at end of 1
st
, 2
nd
 and 3
rd
 month. But average weight gradually increased every month, this 
may be due to increase in moisture content. Assay data showed no significance variation 
during stability studies. 
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Table No. 20: Stability study dissolution data for F-VII formulation 
 
Dissolution 
media 
Sampling 
time 
Storage condition 
40
o
C ± 2
o
C / 75% RH ± 5% RH  
Initial  period 1
st
 Month 2
nd
 Month 3
rd
 Month 
Simulated gastric 
fluid (0.1 N HCl) 
2 hrs 1.6 ± 0.50 1.6 ± 0.75 1.7 ± 0.42 1.7 ± 0.87 
Simulated 
intestinal fluid 
(6.8pH Phosphate 
buffer) 
5 mins 7.34 ± 0.33 7.35 ± 0.17 7.24 ± 0.41 7.31 ± 0.28 
10 mins 19.77 ± 0.67 18.84 ± 0.51 19.54 ± 0.28 19.69 ± 0.46 
15 mins 40.37 ± 0.58 40.58 ± 0.44 40.14 ± 0.29 41.21 ± 0.34 
20 mins 75.28 ± 0.38 74.84 ± 0.24 75.45 ± 0.49 74.67 ± 0.35 
30 mins 87.19 ± 0.22 87.25 ± 0.24 88.41 ± 0.31 88.12 ± 0.21 
45 mins 99.98 ± 0.12 99.96 ± 0.14 98.98 ± 0.22 98.94 ± 0.34 
 
* All the values are expressed as mean ± SD; n=3. 
 
Discussion: 
 F-VII was kept for stability studies. The in vitro dissolution profile was remained 
without any significant changes at the end of 1
st
, 2
nd
 and 3
rd
 months. Hence it was concluded 
that the formulated Rabeprazole sodium delayed release tablets were stable. 
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6. SUMMARY AND CONCLUSION 
SUMMARY 
 
Formulation and evaluation of delayed release tablets of Rabeprazole sodium was 
carried out by performing the preformulation studies, formulation of Rabeprazole sodium 
delayed release tablets, evaluation parameters, in vitro drug release studies and stability 
studies. 
 The preformulation studies of API and drug excipients compatibility studies were 
carried out. 
 IR spectroscopic analysis of drug with excipients was showed that the drug was 
compatible with excipients which were used in the formulation. 
 Rabeprazole delayed release tablets were prepared by direct compression method and 
coated with Protectab Enteric M1 as coating polymer in different concentrations. 
 The prepared powder blend was evaluated for precompression parameters like angle 
of repose, bulk density, tapped density, compressibility index and Hausner ratio. The 
obtained results indicated that it has good flow property for direct compression 
method. 
 The prepared tablets were evaluated for hardness, thickness, weight variation, 
friability, assay and disintegration time. All these parameters were found to be within 
the pharmacopoeial limits in F-VII formulation. 
 In vitro dissolution study was carried out for F-VII formulation. The drug release was 
found to be 99.98 ± 0.12% at 45 mins. 
 Comparative in vitro dissolution study of F-VII formulation showed better drug 
release than the marketed product. 
 The accelerated stability studies of F-VII formulation (F7) at 40oC/75% RH for a 
period of 3 months indicated that there was no significant change in description, 
disintegration time, drug content and in vitro dissolution profiles. The result shows 
that the F-VII formulation was stable. 
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CONCLUSION 
 
Formulation and evaluation of Delayed release tablets of Rabeprazole sodium for the 
effective treatment of duodenal ulcer was successfully carried out. 
The preformulation studies, formulation of Rabeprazole sodium delayed release 
tablets, selection of the best formulation based on disintegration time and in vitro studies for 
delayed release tablets and stability studies were performed. The final product was correlated 
with the marketed product. 
From all the above observations it was concluded that the F-VII formulation was 
better one compared to the other formulations. Thus the study concluded that delayed release 
tablets of Rabeprazole sodium prepared by direct compression method. The tablets were 
coated with Protectab Enteric M1 as a polymer for the effective therapy for duodenal ulcer. 
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